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(57) ABSTRACT 
The present invention provides biodegradable particles (e.g., 
three-dimensional particles) and micelles which can be used 
to encapsulate active agents for delivering to a subject. The 
present invention further provides methods for producing and 
delivering such particles and micelles. Additionally, the 
invention provides vaccination strategies that encompass the 
use of the novel particles and micelles. 
12 Claims, 62 Drawing Sheets 
U.S. Patent Aug. 28, 2012 Sheet 1of62 US 8,252,846 B2 
FIG. 1 
500 - - - - - - 476. 7, - - - - - - - - - - - - - - - - - - - - - - - - -
a-·-~ 0 400 M - - - -
.s ~ 
c: :ii 
g ~ 300 - - - • -
B ~ 
~ ~ 
0 200 - - - - • :::s -u. 




U.S. Patent Aug. 28, 2012 Sheet 2 of 62 US 8,252,846 B2 
....... 


















4b 4c 6a 
IJ II I ,, I .I 





U.S. Patent Aug. 28, 2012 Sheet 4 of 62 US 8,252,846 B2 
FIG. 4 
100o/o 
• pH 1.0 
"CJ 80°/o 




~ 0 40% 
20% 
0 24 48 72 
Time (hours) 
U.S. Patent Aug. 28, 2012 Sheet 5 of 62 US 8,252,846 B2 
U.S. Patent Aug. 28, 2012 Sheet 6 of 62 US 8,252,846 B2 
U.S. Patent Aug. 28, 2012 Sheet 7 of 62 US 8,252,846 B2 
-






Aug. 28, 2012 
0 
0 








US 8,252,846 B2 
FIG. 98 
2 0 
I 0, H2C.XNJlc~~ 
~ CH 2 n 3 4 PH 2 5 
1 6 Hf\ 7 0 12 N H 17 
CH2 J HC s M c1 H c 2' /' I 
8 H2 \ , 2' rf CH2 S "- H 16 
NH 10CH2 1314H 
9 11 H 
15 
...... 2H(14-15} 
































---i--- l I I 1 f l 
8 7 6 5 4 3 2 ppm 
'-T"""""' '--r--' '--,---' '-----r--' '-r'-~---L..~-'---r--'--,.---' 
1.73 3.60 2.05 10.43 4.37 49.83 4.86 6.00 1.47 
































U.S. Patent Aug. 28, 2012 Sheet 11 of 62 US 8,252,846 B2 
FIG. 9C 
Size Distribution by Intensity 
8. . ................................................ -· ...................... . 
Z-Average size (nni): 57.37 : : 
7 . 
6. 
. . . ........ ............. .... ...... ........ ..... ... ..... ... ..... .. ........... . . . . . Polydispersity inde~: 0.267 
-?f!. 5. -~ 
'Ci) 4 . c: ........ ..... ... ..... .... .. ... ..... ... ........ ........ .. ..... .. ...... .... . . . . 
.al . . . . . . c: 3 . . . . .. ...... ...... ... ..... .... .. ... ..... .. ' .................................. . . . . . . . . . . 
2 . 
. . .. ...... ..... .... ........... .. ... ..... ........ ... ...... .... ....... ...... .... . . . . . . . . 
1 . 
. . .... .... .. ....... ......... .. .... ............ ... ......... ...... .. .. ... ..... .... . 
0 
1. 10. 100. 1000. 
Diameter (nm) 
FIG. 90 
Size Distribution by Intensity 
12 . .......................................................................... . 
Z-Average size (n~): 50.91 
10 . ....................... ·:· ...................... -:· ....................... : . . . . . . Polydispersity inde~: 0.164 . . 
8 • . ~ .. ······················:············· ·········:·······················: 
..._... . . . . . . . . . . . 
• ••••••••• ••• •••••••• ••.•••••• •• •••• ••• •••••• •.••••••••••••• ••••••••••I . . . . . . . . . . . . 
4. 
2 . .................................. . 
0 t--~-t--+--+--t-+-t-t-H--~-f---1--+-+-+-t-'f--H'~~t---t--t-t'---f'-t-t-t-t 
1. 10. 100. 1000. 
Diameter (nm) 




















PC Ms PC Ms 
GSH: 100mM 





U.S. Patent Aug. 28, 2012 Sheet 14 of 62 US 8,252,846 B2 
.. 
U.S. Patent Aug. 28, 2012 Sheet 15 of 62 US 8,252,846 B2 
I 1 
U.S. Patent Aug. 28, 2012 Sheet 16 of 62 US 8,252,846 B2 
FIG. 11A 
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FIG. 27 
Nanoparticles Formed with PCADK 
(using sonication) 
• Nanoparticles formed by Solvent Evaporation (Single Emulsion} 
Batch Polymer (mg) PVA {mg) CH3Ct {ul) 
Buffer 
{ml) 
1 20 10 500 5 
2 40 10 500 5 
3 10 10 500 5 
4 20 5 500 5 
5 20 20 500 5 
6 20 10 250 5 
7 20 10 1000 5 
• Conclusion: Particles formed are in 200-300nm range 
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FIG. 29 
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1 
STRATEGIES FOR DELIVERY OF ACTIVE 
AGENTS USING MICELLES AND PARTICLES 
Tbroughout this application various publications are refer-
enced. The disclosures of these publications in their entireties 
are hereby incorporated by reference into this application in 
order to more fully describe the state of the art to which this 
invention pertains. 
This application is a continuation-in-part of U.S. applica-
tion U.S. Ser. No. 11/920,330 filed Nov. 9, 2007, which 
claims the benefit of international application PCT /US2006/ 
018182 which claims the benefit of U.S. provisional applica-
tions U.S. Ser. No. 60/679,480 filed May 10, 2005 and U.S. 
Ser. No. 601720,099 filed Sep. 23, 2005, which are incorpo-
rated herein in full by reference. 
This invention was made with government support under 
NIH/NIAID grant AI048638, AI0564499, AI056947, 
AI057157,AI05726601, and NIH/NIDDK grant DK057665. 
The government has certain rights in the invention. 
FIELD OF THE INVENTION 
2 
responses, or particular classes of T-helper responses (Pu-
lendran, Immunol. Rev., 2004, 199:227-250; Pulendran, J. 
Immunol., 2005, 175:2457-2465; Pulendran & Ahmed, Cell, 
2006, 124:849-863). Despite the importance of adjuvants, 
there is only one adjuvant, alum, licensed for clinical use in 
the United States, and most other experimental adjuvants 
consist of crude extracts of microbes or bacteria, which 
induce potent activation of immune cells, but also result in 
toxicities. Until recently, the mechanism of action of such 
10 adjuvants was not understood. However, recent advances in 
innate immunity have offered a conceptual framework with 
which to understand how adjuvants function. Central to this 
issue is a rare but widely distributed network of cells known 
as dendritic cells (DCs ), which constitute an integral compo-
15 nent of the innate immune system. DCs, which have been 
called 'Nature's adjuvants,' express receptors which can rec-
ognize components of microbes and viruses. Such receptors 
include the Toll-like receptors (TLRs), C-type lectins, and 
CATTERPILLAR proteins, which can "sense" microbial 
20 stimuli, and activate DCs and other immune cells (Pulendran, 
Immunol. Rev., 2004, 199:227-250; Pulendran, J. Immunol., 
2005, 175:2457-2465; Pulendran&Ahmed, Cell, 2006, 124: 
849-863]. It is now clear that DCs play essential roles in The invention relates to particle and micelle based strate-
gies for delivering active agents, such as (i) vaccines; (ii) 
immune modulatory agents, (including TLR ligands or syn- 25 
thetic molecules, which modulate the function of innate 
immune cells such as dendritic cells, or synthetic molecules 
orchestrating the quality and quantity of the immune 
response. 
There are currently some 13 TLRs described in mammals. 
Activating distinct TLRs on DCs induces qualitatively differ-
ent types ofimmune responses (Pulendran, et al, 2001, supra; 
Dillon et al, 2004, supra; Agrawal et al, J. Immunol., 2003, 
171 :4984-4989; Dillon et al, J. Clin. Immunol., 2006, 116: 
916-928). Thus, activating most TLRs can induce Thi 
or siRNA that modulate signaling networks within cells (e.g., 
dendritic or other antigen presenting cells) and/or; (iii) drugs 
that target antigen-presenting cells so as to modulate innate 30 
and adaptive immunity, in a therapeutic or prophylactic set-
ting. responses; activating TLR3, 7 or 9 can induce cytotoxic T 
cells that kill virally infected cells and tumors; and emerging 
evidence suggests that activating TLR2 induces Th2 BACKGROUND OF THE INVENTION 
Harnessing Innate Immunity for Vaccination 
A hallmark of the immune system is its ability to launch 
qualitatively different types of immune responses. Thus for 
example, T-helper I (or Thi) immune responses stimulate 
cytotoxic "killer" T cells, which kill virally infected cells or 
tumors. In contrast, T-helper 2 (or Th2) responses are associ-
ated with antibody production, particularly secretion of IgE 
antibodies, which confer protection against extracellular 
parasites or bacteria or toxins. Furthermore, T regulatory 
responses can suppress over exuberant immune responses, 
and thus limit the immune pathology caused by allergies, 
autoimmunity, transplant rejection, or sepsis like symptoms. 
Given the existence of such diverse types of immune 
responses, and their differential roles in conferring effective 
protection against viruses, tumors, extracellular parasites and 
bacteria, and in regulating deleterious immune responses in 
allergies, autoimmunity, transplantation and sepsis, a "rosetta 
stone" of modern immunology is to learn how to induce 
optimally effective immune responses in various clinical set-
tings. 
In this context, recent advances in immunology have 
revealed a fundamental role for the innate immune system in 
controlling both the quality and quantity of immune 
responses (Pulendran & Ahmed, Cell, 2006, 124:849-863). 
Thus, it has long been known that the immune system is 
unresponsive to most foreign proteins that are injected in a 
soluble, deaggregated form, but when injected together with 
immune-stimulating substances called "adjuvants," these for-
eign proteins can induce robust immunity. In fact it was 
known that the nature of the adjuvant is what determines the 
particular type of immune response that follows, which may 
be biased towards cytotoxic T-cell responses, antibody 
35 responses, (which are associated with antibody responses that 
offer protection against viruses or extracellular bacteria or 
parasites), or even T regulatory or tolerogenic responses, 
(which suppress over exuberant immune responses, and thus 
offer protection against unbridled immunity in allergies, 
40 autoimmunity, sepsis, and transplantation). As such, DCs and 
TLRs and other recognition receptors, represent attractive 
immune modulatory targets for vaccinologists and drug 
developers. Thus learning how to exploit fundamental ele-
ments of the innate immune system such as DCs and TLRs, is 
45 of paramount importance in the development of novel drugs 
and vaccines. 
An important corollary to this notion is that the vast major-
ity of vaccines which have been developed over the past 200 
years, (since the first recorded vaccination trial of Edward 
50 Jenner), have been developed empirically. Therefore, despite 
their successes in controlling various scourges such as small-
pox, polio, TB and yellow fever, we have no knowledge of the 
scientific rationale for how these vaccines stimulate such 
effective immunity. For example, the yellow fever vaccine 
55 I 7D [YF-l 7D] is one of the most effective vaccines known. 
Since its development more than 65 years ago, it has been 
administered to over 400 million people globally. Despite its 
success, the mechanism of its action is not known. Therefore, 
as stated above, the spectacular advances in innate immunity 
60 which have occurred in the last six years or so, offer us a new 
vision with which to understand the modus operandi of such 
"gold standard" vaccines, with a view to using such knowl-
edge to devising future vaccines against emerging and re-
emerging infections of the 21st century. In this context, our 
65 recent findings suggest that the highly effective Yellow Fever 
Vaccine (YF- I 7D) is a potent stimulator ofDCs, and multiple 
TLRs, including TLR 2, 7, 8 and 9 (Querec et al., J. Exp. 
US 8,252,846 B2 
3 
Med., 2006, 203:413-421). Given, the different types of 
immune responses triggered by the distinct TLRs (Pulendran 
et al., 2001, supra; Agrawal et al., J. Immunol., 2003, 171: 
4984-4989; Dillon et al, 2004, supra; Dillon et al, J. Clin. 
Immunol., 2006, 116:916-928), it was tempting to speculate 5 
that by activating multiple TLRs, YF-17D was inducing a 
broad spectrum of immune responses. Indeed, our data sug-
gests that YF-17D triggers a broad spectrum of innate and 
adaptive immune responses (Thl, Th2, cytotoxic T cells, 
neutralizing antibody), and that distinct TLRs control differ- 10 
ent types of this polyvalent immunity (Querec et al., J. Exp. 
Med., 2006, 203:413-421). Eliciting such a broad spectrum of 
immune responses is also likely to be beneficial in designing 
vaccines against other infections, against which no effective 
vaccines currently exist, such as HIV, HCV, malaria, TB, 15 
influenza, anthrax and Ebola, or against tumors. Thus, strat-
egies for designing future vaccines against emerging or re-
emerging infections might benefit from incorporating mul-
tiple TLR ligands plus antigens, plus immune modulatory 
agents, in order to induce multi-pronged immune responses. 20 
Therefore, an important challenge is the development of 
delivery systems which are capable of delivering such 
immune modulatory agents in vivo. 
As described herein, polyketal (PK) particles are a new 
class ofbiomaterials that hydrolyze in a controllable manner 25 
at physiological pH values and degrade into neutral com-
pounds. 
Delivery Systems for Novel Vaccines 
Drug delivery vehicles based on polyesters and polyanhy-
drides have been widely used for the sustained release of 30 
therapeutics because of their excellent biocompatibility pro-
files and slow hydrolysis rates (Anderson, J. M. et al., Adv. 
Drug Delivery Rev., 1997, 28:5-24; Jain, R. A., Biomaterials, 
2000, 21:2475-2490; Mathiowitz, E. et al., J. Appl. Polym. 
Sci., 1988, 35:755-774; Berkland, C. et al., J Controlled 35 
Release, 2004, 94:129-141). However, numerous medical 
applications, such as targeting the acidic environment oflyso-
somes and tumors, require drug delivery systems that undergo 
rapid, pH-sensitive degradation (Stubbs, M. et al., Mal. Med. 
Today, 2000, 6: 15-19; Leroux, J.-C.,Adv. Drug Delivery Rev., 40 
2004, 56:925-926). The majority of degradable polymers 
used for drug delivery cannot fulfill this requirement because 
they are composed of ester linkages, which degrade by base-
catalyzed hydrolysis at physiological pH values. Particles 
made of ester based materials, such as Poly(lactic-glycolic 45 
acid) (PLGA), polyorthoesters, and polyanhydrides, all gen-
erate high quantities of acid when they degrade. This causes 
degradation of protein and DNA therapeutics and the degra-
dation also takes weeks to months. Because the life span of 
mature DCs is around 2 days these materials are not ideal for 50 
vaccine development. Recently, pH sensitive hydrophobic 
microparticles based on poly(orthoesters) and poly(beta-
amino esters) have been successfully used for intracellular 
drug delivery and tumor targeting, thus demonstrating the 
potential of acid-sensitive biomaterials for drug delivery 55 
(Heller, J. et al., Biomacromolecules, 2004, 5:1625-1632; 
Heller, J. et al., Adv. Drug Delivery Rev., 2002, 54: 1015-1039; 
Berry, D. et al., Chem. Biol., 2004, 11 :487-498; Potineni, A. 
et al., J Controlled Release, 2003, 86:223-234). Conse-
quently, there is great interest in developing new strategies for 60 
the synthesis of pH-sensitive biodegradable polymers. 
Vaccines based on recombinant proteins, peptide antigens, 
or DNA vaccines encoding such vaccine antigens, have tre-
mendous therapeutic potential against infectious diseases and 
tumors, in which the antigenic epitopes have been defined. 65 
Such vaccines have been capable of generating protective 
immunity against infectious diseases, in animal models, and 
4 
numerous clinical trials with such vaccines are currently in 
progress (van Endert, PM, Biologicals, 2001, 29:285-8; Pur-
cell, AW et al., Journal of Peptide Science, 2003, 9:255-81; 
Shirai, M. et al., Journal of Virology, 1994, 68:3334-42; Hun-
ziker, IP et al., International Immunology, 2002, 14:615-26). 
However, despite their promise, a major challenge concerns 
the efficient delivery of peptides, proteins, DNA vaccines and 
adjuvants, so as to target the appropriate type of antigen 
presenting cell in order to launch an effective immune 
response. Although promising results have been obtained 
with peptide vaccines composed of lipid conjugates and 
PLGA microparticles, there is still a great need for the devel-
opment of new peptide vaccine delivery vehicles (Ertl, H C J 
eta!., Vaccine, 1996, 14:879-85;Jackson,DCetal., Vaccine, 
1997, 15:1697-705). 
SUMMARY OF THE INVENTION 
The present invention provides biodegradable particles 
(e.g., three-dimensional particles) and micelles which can be 
used to encapsulate active agents for delivering to a subject. 
The present invention further provides methods for producing 
and delivering such particles and micelles. Additionally, the 
invention provides vaccination strategies that encompass the 
use of the novel particles and micelles. 
Hydrophobic Polyketal Particles 
The present invention is directed to new type of hydropho-
bic polymers comprising ketal groups in the polymer back-
bone wherein the ketal groups are arranged in a way such that 
both oxygen atoms are located in the polymer backbone. 
Further, the ketal polymer can be formed via a ketal 
exchange reaction between a ketal and a dial. In accordance 
with the invention, one or more types of the ketals and/or dials 
can be used for the formation of a homopolymer or copoly-
mer. 
Also encompassed by the present invention are polyketal 
polymers which are joined by other polymers (e.g. PEG, 
polyesters, polyamides, polysaccharides, polyethers, or poly-
anhydrides ). The resulting polymers can be alternating 
copolymers, random copolymers, block copolymers, or graft 
copolymers. Polythioketal polymers, mixed polythio-amine 
ketals, polythio-hydroxyl ketals and polyhydroxyl-amine 
ketals are also in the scope of the present invention. 
Polyketal polymers of the invention hydrolyze in aqueous 
solutions into low molecular weight, water soluble alcohols 
and ketones. The advantage of a ketal linkage in the backbone 
is that it degrades under acidic conditions of phagosomes, 
within 1-2 days at pH 5.0. Polyketals can therefore also be 
used for targeting the acidic environments of tumors, inflam-
mation and phago-lysosomes. The degradation does not gen-
erate acidic degradation products. Thus, the ketal polymers 
are suitable for biological use. 
Micelles 
The present invention further provides novel biodegrad-
able crosslinked micelles comprising multiple polymers, 
wherein the polymers are e.g., crosslinked by an external 
crosslinking agent (i.e., agents which are not introduced into 
the polymer chain). The advantage of using of external agents 
is the faster crosslinking reaction compared to a reaction 
wherein only crosslinkable moieties within the polymer are 
used. The external crosslinking agent also decreases the 
chances that the encapsulated is protein destroyed. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a bar graph showing the fluorescence intensity of 
filtered and unfiltered PKNs with FITC-Ova (excitation 494 
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run, emission 520 run). The data shown is the average of two 
samples. The FITC-Ova encapsulation efficiency is 60% (Ex-
ample 3, infra). 
FIG. 2 is a diagrammatic representation showing the syn-
thesis and degradation of Ketal-backbone polymer 5 
(polyketal). (A) Ketal exchange reaction between 1,4-ben-
zenedimethanol and 2,2-dimethoxypropane to produce the 
ketal intermediate 1. (B) Stepwise polymerization of 1 to 
produce polyketal 2. Reaction steps A and B are driven for-
ward by distilling off the methanol byproduct. (C) Formation 10 
of drug-loaded particles by the solvent evaporation method. 
Particles exhibit pH-sensitive degradation into low molecular 
weight excretable compounds (Example 4, infra). 
FIG. 3(A) is a graph showing a GPC trace of polyketal 2 (of 
FIG. 2) in THF (Shimadzu SCL-lOA). Mw=4000, 15 
MjMn =1.54 based on a polystyrene standard (Polymer 
Laboratories, Inc.). Y-axis indicates relative absorbance at 
262 run. FIG. 3(B) shows 1H NMR spectrum ofpolyketal 2 
(of FIG. 2) in CDC13 (Varian Mercury Vx 400); repeating unit 
peaks at 7.3 ppm (4b ), 4.5 ppm ( 4c), and 1.5 ppm (6a). Peaks 20 
at 2.5 and 1.0 are due to triethylamine added to prevent ketal 
hydrolysis. (Example 4, infra) 
FIG. 4 is a line graph showing the hydrolysis kinetics of 
polyketal 2 (of FIG. 2) (finely ground powder) at pH 1.0, 5.0, 
and 7.4. Exponential decay half-lives are 102 h (pH 7.4) and 25 
35 h (pH 5.0). The pH 1.0 control batch was completely 
hydrolyzed before the first time point. (Example 4, infra) 
FIG. 5 shows SEM images of particles made with polyketal 
2 (of FIG. 2). (A,B) Particles using 0.2:1 ratio of PVA to 
polyketal 2 (particle size: 0.5-30 µm). (C) Dexamethasone- 30 
loaded particles made using 1: 1 PV A:polyketal 2 (particle 
size: 200-500 run). Scale bars are (A) SO µm, (B) 3 µm, and 
(C) 4 µm. (Examples 5 and 6, infra) 
FIG. 6 is a schematic representation showing particle for-
mation. A. Step 1: Dissolve polyketal and drug into chloro- 35 
form; dissolve polyvinyl alcohol in water. B. Step 2: Add 
chloroform solution to water and sonicate, generate micron 
sized droplets. Step 3: Let chloroform evaoporate, generates 
particles. (Example 6, infra) 
FIG. 7 is a photograph showing polyketal particles loaded 40 
with Fluorescein are taken up in the liver. Murine liver tissue 
slice is shown releaing fluorescein from PKNs following 
intravenous injection. (Example 6, infra) 
FIG. 8 is a schematic diagram showing a peptide 
crosslinked micelle design and synthesis. Step 1: ISS DNA 45 
and I are mixed to form micelles (uncrosslinked micelle). 
Step 2: These micelles are then crosslinked with the antigenic 
peptide (II) to generate a delivery system that can encapsulate 
both immunostimulatory molecules and peptide antigens. 
After phagocytosis by APCs, the peptide-crosslinked 50 
micelles release their components. (Example 6, infra) 
FIG. 9 shows the synthesis and characterization of PEG-
polylysine thiopyridal. A. is a chemical diagram showing the 
synthesis of PEG-polylysine thiopyridal. B is a lH-NMR 
spectrum of PEG-PLL-thiopyridal in D20. C./D are graphs 55 
depicting the dynamic light scattering analysis of PCMs 
uncross-linked (C) and peptide cross-linked (D). Eis a graph 
showing the crosslinking reaction of cysteines on peptide 
anigen II (FIG. 8). Fis a graph showing the UV analysis of 
crosslinking reaction between peptide anigen II (FIG. 8) and 60 
block copolymer micelles. (Example 6, infra) 
FIG. 10 shows the effect ofGSH on release of peptides and 
DNA. A is a graph showing GSH sensitive peptide release. B 
is a gel elecrophoresis analysis showing GSH sensitive DNA 
release. C is a gel elecrophoresis analysis showing ISS-DNA 65 
is protected from serum nucleases in the PCMs. (Example 6, 
infra) 
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FIG. 11 depicts block copolymer micelles. A depicts the 
chemical structure of PEG-poly (lysine-thio-pyridyl). Bis a 
schematic diagram showing micelle formation. C is a sche-
matic diagram showing crosslinking of micelles.Dis a sche-
matic diagram showing reducing of crosslinked micelles. 
(Example 6, infra) 
FIG. 12 shows the immunology of micelle. A. Confocal 
microscopic analysis of the uptake of SIINFEKL-CFSE 
(SEQ ID NO: 1 )micelles by human monocyte derived DCs. B. 
FACS analysis ofuptake ofmicelle encapsulated SIINFEKL 
peptide (SEQ ID NO: 1) by human monocyte derived DCs. C. 
FACS analysis ofuptake ofmicelle encapsulated SIINFEKL 
peptide (SEQ ID NO:l) by mouse DCs and Macrophages. 
(Example 6, infra) 
FIG. 13 is a bar graph showing micelle formulated SIIN-
FEKL peptide (SEQ ID NO: 1 )induces potent T cell responses 
in-vitro (Example 6, infra). 
FIG.14 shows the immunology ofmicelle.A shows FACS 
analysis of efficient uptake of micelle encapsulated OVA 
protein by mouse DCs and Macrophages.Bis a graph show-
ing that micelle encapsulated OVA/CpG activates DCs in-
vitro. (Example 6, infra) 
FIG. 15 is a graph depicting the immunology of polyketal 
particles. Uptake of polyketal particle (PKN) encapsulated 
U0126 by mouse DCs and Macrophages in-vitro. (Example 
6, infra) 
FIG. 16 is a schematic diagram showing the experimental 
outline for T cell stimulation in-vitro using OVA-OT/1 trans-
genic model. (Example 6, infra) 
FIG. 17 shows the immunology of micelle. A. Left panel is 
the flow cytometery analysis and the right panel is the sum-
mary showing that splenocytes pulsed with micelle formu-
lated antigen induces potent antigen-specific CDS+ T cell 
responses in-vitro. B. Left panel is the flow cytometery analy-
sis and the right panel is the summary showing that DCs 
pulsed with micelle formulated antigens induce potent anti-
gen-specific CDS+ T cell responses in vitro. C. Flow cytom-
etery analysis showing that micelle formulated antigen acti-
vate DCs in-vivo. (Example 6, infra) 
FIG. 18 shows the immunology of micelle and polyketal 
particles. A. Left panel is the flow cytometery analysis and the 
right panel is the summary showing that micelle formulated 
vaccines induce strong antigen-specific CDS+ IFN-
gamma+T cell responses in-vivo. B. Left panel is the flow 
cytometery analysis and the right panel is the s=ary show-
ing that micelle formulated vaccines induce strong antigen-
specific CDS+ TNFa+ T cell responses in-vivo. C. Line 
graphs showing the kinetics of specific CDS+/IFNy+ T cells 
after OVA/CpG vaccination. D. Line graphs showing the 
kinetics of specific CDS+/IFNy+ T cells after OVA+U0126 
PKN vaccination. E. Bar graphs showing that micelle formu-
lated vaccines induce strong antigen specific IgG antibody 
response in-vivo. F. Bar graphs showing that micelle formu-
lated vaccines induce antigen specific IgE and IgM antibody 
response in-vivo. (Example 6, infra) 
FIG. 19 shows polyketals from cyclohexane dimethanol 
(termed PCADK herein with IUPAC designation poly( cyclo-
hexane-1,4-diyl acetone dimethylene ketal)). A. Chemical 
representation showing polyketals from cyclohexane 
dimethanol. B. Line graph showing that PCADK degrades in 
an acid sensitive manner. (Example 6, infra) 
FIG. 20 shows SEM images depicting that particles from 
PCADK can encapsulate the hydrophobic compounds and 
drugs such as rhodhamine red and ebselen. (Example 6, infra) 
FIG. 21 shows line graphs showing that release of 
rhodhamine red from PCADK is pH sensitive. (Example 6, 
infra) 
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FIG. 22 is a chemical representation showing that polyket-
als with almost any aliphatic dial can be made. (Example 6, 
infra) 
FIG. 23 is a photograph showing that FITC labeled 
polyketals are phagocytosed by liver macrophages. (Example 5 
6, infra) 
FIG. 24A is a schematic diagram showing double emulsion 
procedure used to encapsulate catalase and super oxide dis-
mutase in polyketal particles. B is a SEM image of catalase 
containing particles, and fluorescent microscope images of 10 
catalase containing particles. C is a graph showing that cata-
lase particles have enzymatic activity. (Example 6, infra) 
FIG. 25 is a chemical representation showing that polyket-
als made by acyclic diene metathesis (ADMET). 
FIG. 26 is a schematic diagram for the synthesis and acid 15 
degradation of drug loaded particles. 
FIG. 27 is a table showing the conditions used to make 
different rhodhamine containing PCADK particles. 
FIG. 28 shows H-NMR analysis of PK-3. The H-NMR 
spectrum was obtained using a Varian Mercury VX 400 MHz 20 
NMR spectrometer (Palo Alto, Calif.) using CDC13 as the 
solvent. The molar ratio of 1,5-pentanediol to 1,4-cyclohex-
anedimethanol was obtained by obtaining the ratio of areas 
under the peaks a and b, respectively (Example 7, infra). 
FIG. 29 is a schematic showing synthesis of polyketal 25 
copolymers from 1,4-cyclohexanedimethanol, a second dial 
and 2,2-dimethoxypropane. Hydrolysis kinetics of polyketal 
copolymers can be controlled by copolymerization (Example 
7, infra). 
FIG. 30 are graphs showing hydrolysis kinetics of polyket- 30 
als can be tuned by copolymerization. (A) Hydrolysis profiles 
8 
in PBS instead ofNiC12 . Very little fluorescence from GFP is 
seen. (b) PCADK-NTA particles loaded with NiC12 show 
extensive association with GFP (Example 8, infra). 
FIG. 37 is a graph of the Specific Binding curve for 1 % 
NTA-PCADK particles (On-particle ELISA). 1 % NTA-
PCADK particles were charged with Ni and loaded with 
varying concentrations of His-tagged GFP. After extensive 
washing after GFP loading, horseradish peroxidase (HRP) 
conjugated GFP antibody (A-GFP Ab) was incubated with 
the particles (particles suspended at 1 mg particles/ml of 
PBS-T with a 1: 5000 dilution of a-GFP Ab and 1 % goat 
serum) for 2 h at room temperature. Particles were then 
washed with 3 volumes of PBS-T. Colorimetric determina-
tion ofHRP activity was done on a plate reader with different 
amounts of particle per well. I-step Slow TMB-ELISA sub-
strate (3,3',5,5'-tetramethylbenzidene, Pierce) was used at a 
substrate and absorbances measured at 370 nm. Readings 
from 3, 6, and 9 min were compared and shown above. Spe-
cific binding curve suggests that 1 % NTA particles saturate 
with GFP when loaded with 60 ng GFP/mg particle (Example 
8, infra) 
FIG. 38 is a graph of the Specific Binding curve for 10% 
NTA-PCADK particles (On-particle ELISA). 10% NTA-
PCADK particles were charged with Ni and loaded with 
varying concentrations of His-tagged GFP. After extensive 
washing after GFP loading, horseradish peroxidase (HRP) 
conjugated GFP antibody ( a-GFP Ab) was incubated with the 
particles (particles suspended at 1 mg particles/ml of PBS-T 
with a 1 :5000 dilution of a-GFP Ab and 1 % goat serum) for 
2 h at room temperature. Particles were then washed with 3 
volumes of PBS-T. Colorimetric determination ofHRP activ-
ity was done on a plate reader with different amounts of 
particle per well. I-step Slow TMB-ELISA substrate (3,3',5, 
of polyketal copolymers PK! to PK6 in pH 4.5 buffer, and (B) 
hydrolysis profiles of PK! to PK6 in pH 7.4 buffer. Data are 
presented as mean± standard deviation. All experiments were 
conducted in triplicates at 37° C. (Example 7, infra). 
FIG. 31 is a photograph showing SEM images of particles 
formulated with PK3. SEM image of empty particles formu-
lated via double emulsion procedures (Example 7, infra). 
35 5'-tetramethylbenzidene, Pierce) was used at a substrate and 
absorbances measured at 370 nm. Readings from 3, 6, and 9 
min were compared and shown above. Specific binding curve 
suggests that 10% NTA particles saturate with GFP when 
FIG. 32 is a schematic diagram of nitrilotriacetic acid 
(NTA) which, when loaded with nickel (Ni), binds histidine- 40 
tagged proteins (Example 8, infra). 
FIG. 33 is a schematic diagram of a polyketal with a NTA 
linker forming microspheres where active agents are encap-
sulated by the micro sphere and His-tagged proteins are bound 
to the surface of the microsphere. B. A diagram of DOGS- 45 
NTA (Example 8, infra). 
FIG. 34 is a photograph showing SEMmicrographs of10% 
NTA PCADK microparticles (Example 8, infra). 
FIG. 35 is a chart showing the spectrophotometric deter-
mination ofNi depletion in loading solution. PCADK particle 50 
with varying concentrations of NTA-ligand (0%, 1 %, 5%, 
10%) were loaded in NiC12 solution. After incubating the 
particles overnight with agitation, solutions were centrifuged 
and the supematants analyzed for Ni content spectrophoto-
metrically. The supernatant particles with no NTA-ligandhad 55 
a nickel concentration of about 550 mM while 1 %, 5%, and 
10% NTA particles had approximately 500 mM Ni in their 
supemants. This data suggests that the surface of the particles 
is saturated with 1 % NTA-ligand inclusion. Further quanta-
tive testing is currently underway using atomic absorption 60 
spectroscopy (Example 8, infra). 
FIG. 36 are photographs showing that His-tagged Green 
Fluorescent Protein (GFP) is Ni dependent. 10% NTA par-
ticles were charged with Ni, washed extensively and then 
incubated in a 100 nM solution of His-tagged GFP. Particles 65 
were washed extensively with PBS and imaged using fluo-
rescent microscopy. (a) PCADK-NTA particles were loaded 
loaded with 120 ng GFP/mg particle (Example 8, infra). 
FIG. 39 is a graph showing that GFP Binding is reversible. 
Particles loaded with GFP were subjected to an spike of 
imidazole (200 mM final concentration), a competitive bind-
ing ligand to the NTA-Ni complex, and the fluorescence 
intensity of the supernantant measured as a function of time. 
Data suggests that GFP is maximally dissociated at 30 min-
utes in the presence of200 mM imidazole (Example 8, infra). 
FIG. 40 is a chart showing that GFP binding increases with 
amount ofNTA-Ni (Example 8, infra). 
FIG. 41 is a graph showing that His-GFP stably bound to 
NTA-Ni for at least 15 hours (Example 8, infra). 
DETAILED DESCRIPTION OF THE INVENTION 
Definitions 
All scientific and technical terms used in this application 
have meanings commonly used in the art unless otherwise 
specified. As used in this application, the following words or 
phrases have the meanings specified. 
As used herein, the term "micelle" refers to a colloidal 
aggregate of polymer molecules having at least two different 
moieties which are linked to different properties in a liquid 
medium. The difference in the properties can occur due to 
different hydrophobicity/hydrophilicity, polarity, charge or 
charge distribution or other parameters which influence the 
solubility of a molecule. Micelles of the present invention are 
distinguished from and exclude liposomes which are com-
posed of bilayers. 
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As used herein, the term "polymer" refers to a covalently 
linked arrangement of monomeric molecules. The arrange-
ment can be realized in a linear chain or in a branched form. 
The polymer can be a homopolymer which is composed of 
only one type of monomeric molecules, or it can be a copoly-
mer wherein two or more different types of monomers are 
joined in the same polymer chain. When the two different 
monomers are arranged in an alternating fashion, the polymer 
is called an alternating copolymer. In a random copolymer, 
the two different monomers may be arranged in any order. In 
a block copolymer each type of monomer is grouped together. 
A block copolymer can be thought of as two or more 
homopolymers joined together at the ends. When chains of a 
polymer made of one monomer are grafted onto a polymer 
chain of a second monomer a graft copolymer is formed. 
As used herein, the term "particle" or "three-dimensional 
particle" refers to e.g., nanoparticles and/or microparticles. 
According to standard definitions, the term "nanoparticle" 
covers only particle having at least one dimension smaller 
than lOOnm. 
Larger particles which do not fulfill this requirement are 
termed "microparticles". The present invention provides 
three-dimensional particles sized on the nanometer (nm) and 
micron (µm) scale. The particles of the invention can range in 
size from about 50 nm to 1000 µm or from about 200 nm to 
600µm. 
The terms "ketals" and "dials" as used herein encompass 
ketals and dials comprising alkyl, cycloalkyl and aryl groups. 
"Alkyl group" or "aliphatic group" as used herein, is linear or 
branched chain alkyl group. In one embodiment a linear alkyl 
group is preferred. Also included within the definition of alkyl 
are heteroalkyl groups, wherein the heteroatom can be nitro-
gen, oxygen, phosphorus, sulfur and silicon. 
The term "cycloalkyl group" or "cycloaliphatic group", as 
used herein describes a ring-structured alkyl including at least 
three carbon atoms in the ring. In one embodiment, a 
cycloalkyl group having 5 or 6 carbons is preferred. The 
cycloalkyl group also includes a heterocyclic ring, wherein 
the heteroatom can be nitrogen, oxygen, phosphorus, sulfur 
and silicon. 
"Ary! group" or "aromatic group" as used herein, is an 
aromatic aryl ring such as phenyl, heterocyclic aromatic rings 
such as pyridine, furan, thiophene, pyrrole, indole and purine, 
and heterocyclic rings with nitrogen, oxygen, sulfur or phos-
phorus. Included in the definition of alkyl, cycloalkyl and aryl 
groups are substituted alkyl, cycloalkyl and aryl groups. 
These groups can carry one or more substitutions. Suitable 
substitution groups include but are not limited to, halogens, 
amines, hydroxyl groups, carboxylic acids, nitro groups, car-
bonyl and other alkyl, cycloalkyl and aryl groups. 
In order that the invention herein described may be more 
fully understood, the following description is set forth. 
Compositions of the Invention 
Polyketal Polymers of the Invention 
The present invention provides biodegradable hydropho-
bic polyketal polymers comprising multiple ketal groups, 
each ketal group having two oxygen atoms within the poly-
mer backbone. In one embodiment, the biodegradable hydro-
phobic polyketal polymer of the invention is in the form of a 
solid molecule. 
Examples of suitable ketal groups include, but are not 
limited to, 2,2-dioxypropyl group, 2,2-dioxybutyl group, 1,1-
dioxycyclohexyl group or dioxyacetophenyl group. Also in 
the scope of the invention are ketal polymers including ali-
phatic, cycloaliphatic or aromatic ketals containing one or 
more hetero-atom, such as nitrogen, sulfur, oxygen and 
halides. 
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In one embodiment of the invention, the polymer further 
comprises a compound comprising alkyl, aryl, and cycloalkyl 
groups. In this embodiment, the compound may be directly 
attached to the ketal group. 
Examples of suitable alkyl groups include, but are not 
limited to, methyl, ethyl and butyl groups. Examples of suit-
able aryl groups include, but are not limited to, substituted or 
unsubstituted benzyl, phenyl or naphtyl groups, such as, for 
example, a 1,4-dimethylbenzene. Examples of suitable 
10 cycloalkyl groups include, but are not limited to, substituted 
or unsubstituted cyclohexyl, cyclopropyl, cyclopentyl 
groups, such as, for example, 1,4-dimethylcyclohexyl group. 
In a preferred embodiment, the polymer may be poly(l ,4-
15 phenylene-acetone dimethylene ketal). This polymer can be 
synthesized of 2,2-dimethoxypropane and 1,4-benzene 
dimethanol. The polymer may also be a poly(l,4-cyclohex-
ane-acetone dimethylene ketal), which can be synthesized of 
2,2-dimethoxypropane and 1,4-cyclohexane dimethanol. 
20 In another embodiment, the polymer is poly( cyclohexane-
1,4-diyl acetone dimethylene ketal) (PCADK). PCADK is 
made from cyclohexane dimethanol and degrades in an acid 
sensitive marmer into cyclohexane dimethanol and acetone. 
The ketal linkages in PCADK hydrolyze on the order of 
25 weeks under physiologic pH conditions. At the phagosomal 
pH of 4.5, the ketal linkages of PCADK are approximately 
30% hydrolyzed after 10 days. 
In further embodiment of the invention, the polyketal poly-
mer can be any one or more of PK!, PK2, PK3, PK4, PK5 and 
30 PK6 copolymers. These six polyketal copolymers exhibit 
varied hydrolysis kinetics at different pH levels. For example 
at pH 4.5, PK4 is the fastest out of the six copolymers to 
hydrolyze with PK3 having the second faster hydrolysis rate. 
In turn, PK3 has faster hydrolysis kinetics than PK2 or PK5, 
35 while PK2 and PK5 have faster hydrolysis kinetics than PK! 
or PK6. However, at pH 7.4, PK3 is hydrolyzed faster than 
PK4. By altering the copolymer percentage of the polyketals 
of the invention, the hydrolysis kinetics for controllable 
release of an active agent can be fine tuned. 
40 In one embodiment, PK! has a structure as shown in Table 
1 (Example 7) and is made up of at least 2 different monomers 
i.e., repeating units such as random repeating units. In one 
example of PK!, one type of monomer is 1,4,-cyclohex-
anedimethoxy with an x value (i.e. percent component of the 
45 first monomer incorporated into the polymer) of about 98%, 
and the second type of monomer is 1,5-pentanedioxy with a y 
value (i.e. percent component of the second monomer incor-
porated into the polymer) of about 2%. Then value may be 3. 
In this embodiment, PK! is synthesized from two types of 
50 starting compounds, namely, 1,4-cyclohexanedimethanol 
and 1,5-pentanediol. An IUPAC designation for PK! is poly 
( cyclohexane-1,4-diyl acetone dimethylene ketal-co-1,5-
pentane-acetone dimethylene ketal). 
In one embodiment, PK2 has a structure as shown in Table 
55 1 (Example 7) and is made up of at least 2 different monomers 
i.e., repeating units such as random repeating units. In one 
example of PK2, one type of monomer is 1,4,-cyclohex-
anedimethoxy with an x value (i.e. percent component of the 
first monomer incorporated into the polymer) of about 92%, 
60 and the second type of monomer is 1,5-pentanedioxy with a y 
value (i.e. percent component of the second monomer incor-
porated into the polymer) of about 8%. Then value may be 3. 
In this embodiment, PK2 is synthesized from two types of 
starting compounds, namely, 1,4-cyclohexanedimethanol 
65 and 1,5-pentanediol. An IUPAC designation for PK2 is poly 
( cyclohexane-1,4-diyl acetone dimethylene ketal-co-1,5-
pentane-acetone dimethylene ketal. 
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In one embodiment, PK3 has a structure as shown in Table 
1 (Example 7) and is made up of at least 2 different monomers 
i.e., repeating units such as random repeating units. In one 
example of PK3, one type of monomer is 1,4,-cyclohex-
anedimethoxy with an x value (i.e. percent component of the 5 
first monomer incorporated into the polymer) of about 87%, 
and the second type of monomer is 1,5-pentanedioxy with a y 
value (i.e. percent component of the second monomer incor-
porated into the polymer) of about 13%. Then value may be 
3. In this embodiment, PK3 is synthesized from two types of 10 
starting compounds, namely, 1,4-cyclohexanedimethanol 
and 1,5-pentanediol. An IUPAC designation for PK3 is poly 
( cyclohexane-1,4-diyl acetone dimethylene ketal-co-1,5-
pentane-acetone dimethylene ketal. 
In one embodiment, PK4 has a structure as shown in Table 15 
1 (Example 7) and is made up of at least 2 different monomers 
i.e., repeating units such as random repeating units. In one 
example of PK4, one type of monomer is 1,4,-cyclohex-
anedimethoxy with an x value (i.e. percent component of the 
first monomer incorporated into the polymer) of about 97%, 20 
and the second type of monomer is 1,4-butanedioxy with a y 
value (i.e. percent component of the second monomer incor-
porated into the polymer) of about 3%. Then value may be 2. 
In this embodiment, PK4 is synthesized from two types of 
starting compounds, namely, 1,4-cyclohexanedimethanol 25 
and 1,4-butanediol. An IUPAC designation for PK4 is poly 
( cyclohexane-1,4-diyl acetone dimethylene ketal-co-1,4-bu-
tane-acetone dimethylene ketal). 
In one embodiment, PK5 has a structure as shown in Table 
1 (Example 7) and is made up of at least 2 different monomers 30 
i.e., repeating units such as random repeating units. In one 
example of PK5, one type of monomer is 1,4,-cyclohex-
anedimethoxy with an x value (i.e. percent component of the 
first monomer incorporated into the polymer) of about 85%, 
and the second type of monomer is 1,6-hexanedioxy with a y 35 
value (i.e. percent component of the second monomer incor-
porated into the polymer) of about 15%. Then value may be 
4. In this embodiment, PK5 is synthesized from two types of 
starting compounds, namely, 1,4-cyclohexanedimethanol 
and 1,6-hexanediol. An IUPAC designation for PK5 is poly 40 
( cyclohexane-1,4-diyl acetone dimethylene ketal-co-1,6-
hexane-acetone dimethylene ketal). 
In one embodiment, PK6 has a structure as shown in Table 
1 (Example 7) and is made up of at least 2 different monomers 
i.e., repeating units such as random repeating units. In one 45 
example of PK6, one type of monomer is 1,4,-cyclohex-
anedimethoxy with an x value (i.e. percent component of the 
first monomer incorporated into the polymer) of about 87%, 
and the second type of monomer is 1,8-octanedioxy with a y 
value (i.e. percent component of the second monomer incor- 50 
porated into the polymer) of about 13%. Then value may be 
6. In this embodiment, PK6 is synthesized from two types of 
starting compounds, namely, 1,4-cyclohexanedimethanol 
and 1,8-octanediol. An IUPAC designation for PK6 is poly 
( cyclohexane-1,4-diyl acetone dimethylene ketal-co-1,8-oc- 55 
tane-acetone dimethylene ketal). 
The PK1-PK6 copolymers may be synthesized using the 
acetal exchange reaction by copolymerizing 1,4-cyclohex-
anedimethanol with either butanediol, pentanediol, hex-
anediol or octanediol. As shown in Table 1 of Example 7, 60 
infra, a PK! was synthesized with monomer A (1,4-cyclohex-
anedimethanol) plus monomer B (1,5-pentanediol); a PK2 
was synthesized with monomer A (1,4-cyclohexanedimetha-
nol) plus monomer B (1,5-pentanediol); a PK3 was synthe-
sized with monomer A (1,4-cyclohexanedimethanol) plus 65 
monomer B (1,5-pentanediol); a PK4 was synthesized with 
monomer A (1,4-cyclohexanedimethanol) plus monomer B 
12 
(1,4-butanediol); a PK5 was synthesized with monomer A 
(1,4-cyclohexanedimethanol) plus monomer B (1,6-hex-
anediol); a PK6 was synthesized with monomer A (1,4-cy-
clohexanedimethanol) plus monomer B (1,8-octanediol). 
In another embodiment of the invention, the PK!, PK2, 
PK3, PK4, PK5 and PK6 copolymers of the invention can be 
intermingled to change or fine tune the release rate profile for 
attached active agents. For example, a polyketal with fast 
hydrolysis kinetics (e.g., PK4 or PK3) can be mixed with a 
polyketal with slower hydrolysis kinetics (e.g., PK! or PK6) 
and co-administered to a subject. The active agent joined to 
PK4 or PK3 will be released in a subject quickly to provide 
the subject with an immediate release (IR) dose of active 
agent, while the active agent joined to PK! or PK6 will be 
released at a slower rate allowing a gradual or extended 
release (ER) of the active agent in the subject. 
In an embodiment of the invention, the biodegradable 
hydrophobic polyketal polymers comprises (1) multiple ketal 
groups, each ketal group having two oxygen atoms within the 
polymer backbone and (1) a linker. The ketal groups may 
comprise a 2,2-dioxypropyl group. 
Biodegradable Polyketal Particles of the Invention 
The invention further provides biodegradable particles 
comprising the polyketal polymers of the invention. The sizes 
of the particles can vary. For example, biodegradable particles 
can be made at nanometer (nm) or micron (µm) scale e.g., to 
form nanoparticles or microparticles. The particles of the 
invention can range in size from about 50 nm to 1000 µm. In 
one embodiment, the particles range in size from about 200 
nm to 600 µm. In another embodiment, the particles range in 
size from about 1 µm to 10 µm, 10 µm to 20 µm. 20 µm to 30 
µm, 30 µm to 40 µm or 40 µm to 50 µm. In yet another 
embodiment, the particles range in size from about 1 µm to 50 
µm. A preferred particle size is between about 50 and 1000 
nm, more preferred between about 200 and 600 nm. Another 
preferred particle size is about 30 µm. 
The preferred size of a suitable polyketal polymer to form 
the biodegradable particle is between about 0.5 kDa and 
about 2 MDa, more preferred between 1 and about 150 kDa, 
most preferred between about 4 and about 6 kDa. In accor-
dance with the invention, the number of the monomers in the 
polymer can range from about 2 to about 20,000, preferably 
about 10 to about 1,000, more preferably about 10 to about 
50. 
Polyketal polymers of the invention hydrolyze in aqueous 
solutions into low molecular weight, water soluble alcohols 
and ketones. For example, the degradation of poly(alkyl-
acetone dimethylene ketal) is acid sensitive, with a half-life of 
102.0 hat pH 7.4 and 35.0 hat pH 5.0. The advantage ofa 
ketal linkage in the backbone is that it degrades under acidic 
conditions of phagosomes, within 1-2 days at pH 5.0. 
Polyketals can therefore also be used for targeting the acidic 
environments of tumors, inflammation and phago-lysosomes. 
The degradation also does not generate acidic degradation 
products. Thus, the ketal polymers are suitable for biological 
use. 
In accordance with the practice of the invention, the 
polyketal polymer particles can further comprise one or more 
active agents. 
In one embodiment of the invention, the biodegradable 
particle of the invention comprises: (a) a biodegradable 
hydrophobic polyketal polymers comprising multiple ketal 
groups, each ketal group having two oxygen atoms within the 
polymer backbone and (b) a linker. Suitable polymers to form 
the particles of the invention include PCADK and PK1-PK6. 
In one embodiment of the invention, the polyketal polymer 
particle can further comprise one or more linkers which can 
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bind an active agent. Multiple linkers of the same or different 
types can be attached to a polymer particle. The linkers are 
attached to the surfaces of the particles i.e., the linkers are 
exposed to the solvent or aqueous solution surrounding the 
particles. 
In one embodiment, the biodegradable particle of the 
invention comprises (a) one or more of PK!, PK2, PK3, PK4, 
PK5 or PK6 (which can optionally comprise a linker), and (b) 
an active agent. In another embodiment of the invention, the 
biodegradable particle of the invention comprises (a) 
PCADK (which can optionally comprise a linker) and (b) an 
active agent. 
In accord with the practice of the invention, the particles 
can comprise a single population of polyketals or a mixed 
population. 
Active Agents of the Invention 
14 
molecules or fragments thereof, or naturally-occurring or 
synthetic. Examples include, but are not limited to, a non-
toxic form of cholera toxin (Braun et al., J. Exp. Med. 189: 
541-552, 1999), certain forms of Candida albicans (d'Ostiani 
5 et al., J. Exp. Med. 191:1661-1674, 2000), or P. gingivalis 
LPS (Pulendran et al., J. Immunol. 167:5067-5076, 2001). 
Examples of bacterial lipopeptides include bacterial cell 
wall lipopeptides which differ in their fatty acid chain of the 
N-terminal cysteines, such as diacylated and triacylated 
10 lipopeptides. For example, diacylated lipopeptides include 
Macrophage Activating Lipopeptide 2 kilo-Dalton from 
Mycoplasma fermentans or fragments thereof or synthetic 
analogues (e.g., MALP2, Pam2CSK4, 
Pam2CGNNDESNISFKEK, (SEQ ID N0:2), and 
15 Pam2CGNNDESNISFKEK-SK4(SEQ ID N0:3)). The tria-
cylated lipopeptides include Pam3cys {S-[2,3-bis (palmitoy-
loxy )-(2-RS )-propy l]-N-palmitoy 1-R-Cys-S-Ser-Lys4-0 H)} 
(Takeuchi, et al., 2001 International Immunology 13:933-
As used herein, the term "active agent" refers to a protein, 
peptide, nucleic acid (DNA or RNA) or organic molecule, and 
other synthetic nucleic acid molecules, siRNA molecules, or 
antisense molecules. The active agent can be a therapeutic, 20 
prophylactic or diagnostic agent. The therapeutic agent can 
940). 
In an embodiment, the agonist specifically effects TLR-2 
or a receptor(s) bound by SEA (with respect to SEA, see 
MacDonald et al., J. Immunol. 167:1982-1988, 2001). Here 
too, the agonist can be, but is not limited to, a natural ligand, 
a biologically active fragment thereof, or a small or synthetic 
be an immunomodulatory agent such as specific ligands for 
RIG-I or TLRs, or C-type lectins (such as dectin-1 and DC-
SIGN) or caterpillar proteins, or combinations of specific 
TLR ligands, or synthetic molecules or siRNAs which inhibit 
regulatory signaling networks with DCs and macrophages. 
The active agent can further include proteins (e.g. recombi-
nant proteins), peptides, carbohydrates, nucleic acids, small 
molecules (e.g., kinase inhibitors, phosphatase inhibitor, 
cytokine inhibitors, small molecule antioxidant mimetics, 
receptor blockers, cytoskeletal rearrangement inhibitors, 
small molecule receptor activators.), imaging agents, vaccine 
antigens, DNA vaccines, or vaccines themselves, such as the 
influenza vaccine. Finally, an active agent can comprise anti-
bodies that target, stimulate, modulate or inhibit subsets of 
DCs including Langerhans cells, dermal DCs, myeloid DCs, 
interstitial DCs, plasmacytoid DCs, or subsets of monocytes, 
and macrophages. Thus surface of these particles can be 
modified to contain targeting groups such as, for example, 
antibodies against subsets of dendritic cells, or proteins which 
stimulate subsets of dendritic cells, or macrophages such as 
CD40L, DEC-205, CD! le, langerin, MARCO, 33Dl etc. 
Examples of suitable active agents include, but are not 
limited to: (1) agonists and antagonists ofTLRs (e.g., TLR-2, 
TLR-3, TLR-4, TLR-5, TLR-7, TLR-8, TLR-9, TLR-10, and 
TLR-11 ), (2) agonists and antagonists of the receptor(s) acti-
vated by schistosome egg antigen (SEA), (3) molecules that 
stimulate or inhibit the expression or activity of a component 
of an intracellular signaling pathway that transduces the sig-
nal generated by activation of either of these types ofrecep-
tors, ( 4) agents that stimulate or inhibit a transcription factor 
that is induced or stabilized by one or more of these signaling 
pathways, and (5) inhibitors of a regulatory pathway(s) 
within dendritic cells, macrophages or antigen-presenting 
cells. 
Examples of agonists include, but are not limited to, pep-
tidoglycans (0. Takeuchi, et al., 1999 Immunity 11 :443-451) 
or zymosans (Dillon et al, 2006 J. Clin. Invest. 116(4):916-
28). A. Ozinsky, et al., 2000 Proc. Natl. Acad. Sci. USA 
97:13766-13771). The agonists also include bacterial 
lipopeptides (e.g., diacylated and triacylated lipopeptides ), 
lipoteichoic acid, lipoarabinomannan, phenol-soluble modu-
lin, glycoinositolphospholipdis, glycolipids, porins, atypical 
LPS from Leptospira interrogns or Porphyromonas gingiva-
lis, or HSP70 (for a review see K Takeda, et al., 2003 Annu. 
Rev. Immunol. 21:335-376). The agonists can be isolated 
and/or highly purified molecules. The agonists include whole 
25 molecule. Other useful agonists may include anon-toxic form 
of cholera toxin (Braun et al., J. Exp. Med. 189:541-552, 
1999), certain forms of Candida albicans ( d'Ostiani et al., J. 
Exp. Med. 191:1661-1674, 2000), or Porphyromonas gingi-
valis LPS (Pulendran et al., J. Immunol. 167:5067-5076, 
30 2001). These agents fail to induce IL-12(p70) and stimulate 
Th2-like responses. 
The agonists can be agonists of TLR-4 (which bias the 
immune response toward the Th response, e.g. THI) include 
Taxol, fusion protein from Rous sarcomavirus, envelope pro-
35 teins from MMTV, Hsp60 from Chlamydia pneumoniae or 
Hsp60 or Hsp70 from the host. Other host factors that agonize 
TLR-3 include the type III repeat extra domain A offibronec-
tin, oligosaccharides ofhyaluronic acid, polysaccharide frag-
ments ofheparan sulfate, and fibrinogen. A number of syn-
40 thetic compounds serve as agonists of TLR-7 (e.g., 
imidazoquinolin (imiquimod and R-848), loxoribine, bropir-
imine, and others that are structurally related to nucleic 
acids). 
Additional examples of suitable active agents include 
45 inhibitors of ERK, c-Fos, Foxp3, PI3 kinase, Akt, JNK, p38, 
NF-Kb, STAT 1, STAT2, IRF3, IRF7, IFN-alpha signaling or 
combinations thereof. Suitable active agents can further 
include inhibitors of SOCSl-7 proteins. Such inhibitors can 
be a small molecule, or a peptide, protein or nucleic acid (e.g., 
50 siRNA or anti sense). 
The agonist can be an exogenous or endogenous ligand, 
many of which are known in the art. The novel screening 
methods described below, particularly those that feature 
detecting TLR binding or activation, can be used to identify 
55 other ligands (whether naturally occurring molecules, frag-
ments or derivatives thereof, antibodies, other peptides or 
protein-containing complexes, or synthetic ligands). For 
example, exogenous ligands of TLR-2 include LPS (li-
popolysaccharide; a component of the outer membrane of 
60 Gram-negative bacteria), yeast-particle zymosan, bacterial 
peptidoglycans, lipoproteins from bacteria and mycoplas-
mas, and GPI anchor from Trypanosoma cruzi; endogenous 
ligands include heat shock (or "stress") proteins (e.g., an 
Hsp60 from, for example, a bacterial or mycobacterial patho-
65 gen) and surfactant protein-A. Exogenous ligands ofTLR-3 
include poly(I:C) (viral dsNRA); exogenous ligands of 
TLR-4 include LPS, and respiratory syncytial virus (endog-
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enous ligands include stress proteins such as an Hsp60 or 
Hsp70, saturated fatty acids, unsaturated fatty acids, hyalu-
ronic acid and fragments thereof, and surfactant protein-A). 
Flagellin is an exogenous ligand ofTLR-5. CpG (cytosine-
guanine repeat) DNA and dsDNA are exogenous and endog- 5 
enous ligands, respectively, ofTLR-9. See Zuany-Amorim et 
al., Nature Reviews I :797-807, 2002, and Takeda et al., Ann. 
Rev. Immunol. 21:355-376, 2003. 
Suitable oncogenes and tumor suppressor genes include 
neu, EGF, ras (including H, K, and N ras), p53, Retinoblas-
toma tumor suppressor gene (Rb), Wilm' s Tumor Gene Prod-
uct, Phosphotyrosine Phosphatase (PTPase ), and nm23. Suit-
able toxins include Pseudomonas exotoxin A and S; 
diphtheria toxin (DT); E. coli LT toxins, Shiga toxin, Shiga-
like toxins (SLT-1, -2), ricin, abrin, supporin, and gelonin. 
Active agents can include enzymes. Suitable enzymes 
include thymidine kinase (TK), xanthine-guanine phospho-
ribosyltransferase (GPT) gene fromE. coli or E.coli cytosine 
deaminase (CD), or hypoxanthine phosphoribosyl trans-
ferase (HPRT). 
Additional examples of suitable active agents include (a) 
Active agents can include cytokines. Suitable cytokines 
15 
include interferons, GM-CSF, interleukins, tumor necrosis 
factor (TNF) (Wong G, et al., Science 1985; 228:810); 
W09323034 (1993); Horisberger M.A., et al., Journal of 
Virology, 1990 Mar., 64(3):1171-81; Li Y P et al., Journal of 
Immunology, Feb. I, 1992, 148(3):788-94; Pizarro T. T., et al. 
an agent that inhibits the expression or activity of an AP-I 10 
transcription factor in a dendritic cell, (b) a dendritic cell 
treated in culture with an agent that inhibits the expression or 
activity of an AP- I transcription factor, or ( c) syngeneic T 
cells stimulated in culture with dendritic cells treated as 
described in (b ). The transcription factor can include c-fos, 
fos-B, Foxp3, or c-jun, and the agent that inhibits expression 
(of the transcription factor or of any component of the path-
ways described herein (these components are known in the 
art)) can be an antisense oligonucleotide or an RNAi mol-
ecule that specifically inhibits c-fos, fos-B, Foxp3, or c-jun 
expression (or the expression of a kinase, phosphatase, or 
other component of the signaling pathways). The inhibitory 
active agents discussed in the context of the present biode-
gradable particles can also be antibodies (or variants thereof 
(e.g., single-chain antibodies or humanized antibodies); pref-
erably the antibodies are monoclonal antibodies). 
20 Transplantation, 1993 Aug., 56(2):399-404). (Breviario F., et 
al., Journal of Biological Chemistry, Nov. 5, 1992, 267(31): 
22190-7; Espinoza-Delgado I., et al., Journal oflmmunology, 
Nov. I, 1992, 149(9):2961-8; Algate P.A., et al., Blood, 1994 
May I, 83(9):2459-68; Cluitmans F. H., et al., Annals of 
25 Hematology, 1994 Jun., 68(6):293-8; Martinez 0. M., et al., 
Transplantation, 1993 May, 55(5): 1159-66. 
In another embodiment, the active agent is an antagonist 
(e.g., inhibitor or suppressor) of an intracellular pathway that 
impairs TLR2 signaling or activation. The antagonists 
include gram negative LPS, Taxol, RSV fusion protein, 
MMTV envelope protein, HSP60, HSP70, Type III repeat 
extra domain A of fibronectin, oligosaccharides ofhyaluronic 
acid, oligosaccharide fragments of heparan sulfate, fibrino-
gen and flagellin (for a review see K Takeda, et al., 2003 
Annu. Rev. Immunol. 21:335-376). 
In an additional embodiment, the active agent is an antago-
nist of an intracellular pathway that impairs SEA signaling or 
activation. In one other embodiment, the molecule is an 
antagonist of a JNK 1/2 pathway. In another embodiment, the 
molecule is CpG DNA which activates p38 and ERK (A-KYi, 
et al., 2002 The Journal oflmmunolgy 168:4711-4720). 
In another embodiment, the active agent is an inhibitor of 
ERK 1h which can inhibit maturation of dendritic cells and 
thus enhancing an ILl2 and Thi response. Examples of the 
molecule include but are not limited to PD98059 and UOl26 
(A. Puig-Kroger, et al., 2001Blood98:2175-2182). 
Active agents can include Growth factors. Growth factors 
include Transforming Growth Factor-alpha. (TGF-alpha.) 
and beta (TGF-beta), cytokine colony stimulating factors 
30 (Shimane M., et al., Biochemical and Biophysical Research 
Communications, Feb. 28, 1994, 199(1):26-32; Kay A. B., et 
al., Journal of Experimental Medicine, Mar. I, 1991, 173(3): 
775-8; de Wit H, et al., 1994 Feb., 86(2):259-64; Sprecher E., 
35 
et al., Archives ofVirology, 1992, 126(1-4):253-69). 
Active agents can further include the proteins catalase, 
superoxide dismutase, glutathione peroxidase, nitric oxide 
synthase. 
The active agents of the invention can be can be naturally 
40 occurring, synthetic, or recombinantly produced, and 
includes, but are not limited to, any microbial or viral com-
ponent or derivative thereof, including any component that is 
part of the structure of, or is produced by, the microbial cell or 
virus including, but not limited to, a cell wall, a coat protein, 
45 an extracellular protein, an intracellular protein, any toxic or 
non-toxic compound, a carbohydrate, a protein-carbohydrate 
complex, or any other component of a microbial cell or virus. 
The microbial cell or virus can be pathological. 
In another embodiment, the active agent inhibits c-fos sig-
naling thus enhancing an IL12 and Thi response. Such mol-
ecules include a DEF domain mutant of c-fos or any polypep-
tide having a DEF domain mutation (L. 0. Murphy, et al., 50 
2002 Nature Cell Biology 4:556-564 and Supplementary 
information pages 1-3), including: rat Fra-1, and Fra-2; 
mouse FosB, JunD, c-Jun, c-Myc, and Egr-1; and human 
JunB, N-Myc, and mPerl. 
Linkers of the Invention 
The polyketals of the invention (e.g., in a particle embodi-
ment) may further comprise one or more linkers. The linkers 
can be of the same type or can include a mixture of different 
types attached to the polyketal polymers. The linkers can be 
attached to the surfaces of the polyketal polymers e.g., the 
Active agents can include nucleic acids such as DNA, 
RNA, anti-sense oligonucleotide or siRNA. Suitable 
examples of DNA include therapeutic genes. Examples of 
therapeutic genes include suicide genes. These are genes 
sequences, the expression of which produces a protein or 
agent that inhibits tumor cell growth or tumor cell death. 
Suicide genes include genes encoding enzymes, oncogenes, 
tumor suppressor genes, genes encoding toxins, genes encod-
ing cytokines, or a gene encoding oncostatin. The purpose of 
the therapeutic gene is to inhibit the growth of or kill cancer 
cell or produce cytokines or other cytotoxic agents which 
directly or indirectly inhibit the growth of or kill the cancer 
cell. 
55 linkers can be exposed to the solvent or aqueous solution 
surrounding the particles. 
The linker can range in size from 1-1000 nm or 100-200, 
000 Da. In one embodiment of the invention, the linker can 
range in size from 1-10 nm, 10-50 nm, 50-100 nm, 100-200 
60 nm, 200-300 nm, 300-400 nm, 400-500 nm, 500-600 nm, 
600-700 nm, 700-800 nm, 800-900 nm and 900-1000 nm. In 
another embodiment of the invention, the linker can range in 
size from I 00-10,000 Da, I 0,000-50,000 Da, 50,000-100,000 
Da, 100,000-150,000 Da and 150,000-200,000 Da. In yet 
65 another embodiment of the invention, the linker can be about 
200-300 Da, 10,000 Da, 40,000 Da, 64,000 Da or 150,000 Da 
ms1ze. 
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The linker can be a protein, polypeptide, nucleic acid or 
chemical compound. Examples of protein or polypeptide 
linkers include, but are not limited to, an amino acid sequence 
such as arginine-aspartic acid-glycine (RDG), hemoglobin, 
glutathione-S-transferase (GST), streptavidin or an antibody. 
Examples of nucleic acid linkers include, but are not limited 
to, RNA, DNA (e.g., ssDNA such as a 4 to 50 nucleic acid 
long tract of Poly A or Poly T sequence) or synthetic ana-
logues. Examples of chemical compounds that can be used as 
linkers include, but are not limited to, polycarboxylic acid 
(e.g., polyacrylic acid) or chelating agents such as nitrilotri-
acetic acid (NTA) ligand, bipyradol and EDTA. Chelating 
agents bind to metal ions (e.g., nickel, zinc, copper, etc.) with 
the metal ions in tum facilitate binding of an active agent to 
the linker. The linker tethers or joins (e.g., via a noncovalent 
association) an active agent to the polyketal of the invention. 
The linker can bind to active agents including, but not 
limited to, a protein, peptide, nucleic acid and/or carbohy-
drate. In one embodiment, the protein, peptide and/or carbo-
hydrate further comprises a histidine tag. The histidine tag 
can comprise about 2-8 histidines. For example, in one 
embodiment, the histidine tag comprises about 6 histidines. 
The protein so bound to the linker can be a therapeutic, 
prophylactic or diagnostic protein. 
18 
groups, azides, enzyme cleavable linkages, and urethanes, 
with Schiff bases, thiols and ketones being preferred in one 
embodiment of the present application (O'Reilly et al., 2005 
Chem. Mater., 17(24):5976-5988; Hanker et al., 2005 Science 
309(5738):1200-05; Le, Z. et al., 2005 Langmuir 21(25): 
11999-12006; Example 1, FIG. 9). 
In another aspect of the present invention, the external 
crosslinking agent comprises an antigen. Examples of suit-
able antigens include, but are not limited to, proteins or pep-
10 tides. The antigens can be naturally occurring, chemically 
synthesized or recombinantly made. Specific examples of 
suitable protein or peptide antigens include, but are not lim-
ited to, HIV antigens such as gp120 protein (or fragment 
thereof), TAT protein (or fragment thereof), NEF protein (or 
15 fragment thereof), HCV protein (or fragment thereof), and 
env protein (or fragment thereof). A preferred antigen 
includes a gp 120 peptide antigen chemically synthesized and 
modified to contain four additional cysteine residues to create 
therein additional disulfide bonds. Any antigen having 
20 crosslinkable groups can be used. Antigens not having or 
having few crosslinkable groups can be modified (e.g., 
chemically modified) to comprise crosslinkable thiol groups, 
azides, alkynes, amines, maleimides, vinyl sulfones, ketones, 
hydrazines and thioesters. 
Polymers to be used for micelle formation can be 
homopolymers or copolymers, such as block copolymers or 
graft polymers. Examples of suitable polymers include, but 
are not limited to, PEG block copolymers, such as PEG-
polyamino acids, for example, PEG-polylysine, PEG-poly-
In accordance with the practice of the invention, the thera- 25 
peutic protein can be an immunomodulatory protein. For 
example, the immunomodulatory protein can include, but is 
not limited to: (a) a ligand for any ofTLR 2, 3, 4, 5, 7, 8, 9, 10 
and 11 or combination thereof, (b) an inhibitor of a regulatory 
pathway within dendritic cells, macrophages or antigen-pre-
senting cells; and (c) a ligand for RIG-1, any C-type lectins 
including dectin-1 and DC-SIGN, or Caterpillar proteins The 
inhibitor of a regulatory pathway can include inhibitors of: (a) 
ERK, c-Fos, Foxp3, PI3 kinase,Akt, JNK,p38, NF-Kb, STAT 
30 glutamic acid, PEG-polyaspartic acid or PEG-polyarginine; 
PEG-polyesters, PEG-polyurethane, PEG-PPO, modified or 
unmodified, PEG-polyacrylate or PEG-polymethacrylate, 
synthesized by atom transfer polymerization, where the PEG 
acts as an initiator. To facilitate polymer crosslinking, the 
1, STAT2, IRF3, IRF7, IFN-alpha signaling; or (b) a SOCS 1, 
2, 3, or other SOCS protein. 
Additional suitable examples of proteins to bind to the 
linker include growth factors, cytokines, antioxidant 
enzymes, antibodies, erythropoietin (EPO), receptor ligand. 
In one embodiment, a polyketal of the invention (e.g., 
PCADK or any of PK! to PK6) comprises a NTA linker. The 
NTA linker can be loaded with nickel ions to produce a 
NTA-Ni linker that binds histidine tagged proteins. 
Micelles of the Invention 
The present invention further provides a biodegradable 
crosslinked micelle comprising multiple polymers of the 
invention. The polymers can be crosslinked by an external 
crosslinking agent. External crosslinking agents as used 
herein are agents which are not introduced into the polymer 
chain. The advantage of using of external agents is the faster 
crosslinking reaction compared to a reaction wherein only 
crosslinkable moieties within the polymer are used. The 
external crosslinking agent also reduces the probability that 
the encapsulated protein will be destroyed. 
In one aspect of the present invention, suitable crosslinking 
agents are compounds which comprise at least two thiol 
groups. Examples of suitable crosslinking agents include, but 
are not limited to, ethylene glycol dithiol, aliphatic dithiols, 
dithiols which are connected by ketal linkages, and diamine 
containing molecules. The advantage of thiol groups is the 
sensitivity to reducing conditions, thus enabling an easy deg-
radation of the micelle. Other crosslinking strategies include, 
but are not limited to, crosslinking by amines, esters, carbon-
ates, thioesters, Schiff bases, vicinal dials, alkenes and 
alkynes, ketals, ketals orthoesters, thio-ketals, thio-orthoe-
sters, sily-ketals, phenyl boronic acid-dial complexes, car-
bon-carbon bonds, sulfones, phosphate containing functional 
35 polymer can be modified to include chemical groups includ-
ing, but not limited to, amines, esters, carbonates, thioesters, 
Schiff bases, vicinal dials, alkenes and alkynes, ketals, ketals 
orthoesters, thio-ketals, thio-orthoesters, sily-ketals, phenyl 
boronic acid-dial complexes, carbon-carbon bonds, sulfones, 
40 phosphate containing functional groups, azides, enzyme 
cleavable linkages, and urethanes, with Schiff bases, thiols 
and ketones being preferred in one embodiment of the present 
invention. These groups can be introduced via chemical reac-
tions known in the art, such as, among others, Michael addi-
45 tion or acylation (Example 1, FIG. 9). In one preferred 
embodiment the modified polymer is PEG-poly lysine thiopy-
ridal (FIG. 9). 
The polymethacrylate or polyacrylate block can contain 
modifications to allow for assembly with vaccine components 
50 and crosslinking. For example a polyacrylate block can be a 
block copolymer consisting of polydimethylamino-acryalte-
poly-glycidyl acrylate. Homopolymer ofrandom copolymers 
composed of various acrylate or methacrylate monomers 
capable of forming micelles with vaccine components are 
55 also in the scope of the present invention. 
In another aspect of the present invention the micelle can 
further comprise one or more active agents. Examples of 
suitable active agents are found herein, supra. 
In accordance with the practice of the invention, the inter-
60 action between the micelle and the active agent can be elec-
trostatic or hydrophobic or can occur due to hydrogen bond 
formation or molecular recognition depending on the type of 
polymer and agent. The surface of this micelle can be modi-
fied to contain targeting groups such as, for example, anti-
65 bodies against dendritic cells, or proteins which stimulate 
subsets of dendritic cells, or macrophages such as CD40L, 
DEC-205, CD! le, langerin, MARCO, 33D 1 etc. 
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In one embodiment, the micelle is designed to deliver 
peptide antigens and immunomodulatory molecules to anti-
gen-presenting cells (APCs ). In this embodiment, the micelle 
comprises immunomodulatory molecules, peptide antigens 
and a copolymer. The peptide antigen acts as a crosslinker 
which allows the peptide antigen to be efficiently encapsu-
lated into the peptide crosslinked micelles (PCMs) and also 
stabilizes them against degradation by serum components 
20 
Further Modifications of the Biodegradable Particles and 
Micelles of the Invention 
The biodegradable particle or micelles can be further 
modified to incorporate antibodies or other molecules which 
target (1) specific receptors on particular subsets of DCs or 
macrophages or monocytes, including Langerhans cells, der-
mal DCs, myeloid DCs, plasmacytoid DCs or (2) specific 
receptors on antigen-presenting cells, such as DEC205, Lan-
gerin, DC-SIGN, dectin-1, 33Dl, MARCO. In another embodiment, the micelle can be used to encap-
sulate peptide or protein antigens together with immuno-
modulatory agents including multiple TLR ligands, or mol-
ecules such as synthetic compounds or siRNA that modulate 
signaling networks within cells (e.g., dendritic cells or other 
antigen presenting cells). The micelle targets dendritic cells 
and macrophages through their nanometer dimensions, as 
such cells robustly internalize nanometer sized materials, 
through phagocytosis. The micelles are crosslinked by 
crosslinking agents comprising disulfide linkages, which 
should stabilize them against decomposition induced by 
serum proteins. In the further embodiment of the invention, 
the micelle has a size of 5 to 50 microns. 
10 Pharmaceutical Compositions of the Invention 
The present invention provides a pharmaceutical compo-
sition comprising the polymer (which can optionally com-
prise a linker) of the invention. In one embodiment, the 
present invention provides a pharmaceutical composition 
15 comprising the particle (which can optionally comprise a 
linker) of the invention. In another embodiment, the present 
invention provides a pharmaceutical composition comprising 
the micelle (which can optionally comprise a linker) of the 
invention. The polymer of the invention, whether in the form 
20 of a particle or micelle, can further comprise an active agent. 
In another embodiment, the polymers forming the micelle 
For example, in one embodiment, the present invention pro-
vides a pharmaceutical composition comprising PCADK, 
PK!, PK2, PK3, PK4, PK5 and/or PK6 particles with a linker 
bound to an active agent. of the invention further comprise a linker. The linker allows 
for dual delivery of one or more active agents, via encapsu-
lation of the active agents by the micelle or attachment to the 
micelle. 
25 Methods of the Invention 
After phagocytosis, the biodegradable particles and 
micelles of the invention will break down, and the encapsu-
lated material such as peptide or antigens, and immune stimu- 30 
latory agents [ e.g: ISS DNA, TLR 7/s, TLR 3 ligands such as 
ss RNA, TLR 2 ligands, and inhibitors of regulatory pathways 
such as the ERK, c-Fos or Foxp3 pathway], will be released 
into the dendritic cell, or macrophage, and the immunomodu-
35 
latory agent will induce the antigen-presenting cells, to 
secrete a variety of cytokines. This combination of signals 
will result in the optimal activation ofT cells, and inhibition 
ofregulatory T cells and dendritic cells. 
The micelles of the invention can include active agents 40 
such as vaccines composed of antigens from the relevant 
pathogen, together with immune modulatory agents [ e.g: ISS 
DNA, TLR 7/s ligands such as ss RNA, TLR 2 ligands, and 
inhibitors ofregulatory pathways such as inhibitors of ERK, 
c-Fos or Foxp3, PI3 kinase, Akt, SOCS 1-7 proteins, or 45 
siRNA molecules or antisense molecules that inhibit such 
regulatory pathways] 
The invention also provides methods for reversibly modi-
fying proteins so that they have the appropriate charge to be 
encapsulated in the micelles. This strategy is based on react- 50 
ing the amine groups of said protein with a compound, gen-
erating additional negative charges for every amine group, 
and rendering the protein negative. The modified protein will 
then be encapsulated in the micelle, crosslinked and then the 
pH will be reduced in order to remove the inserted compound 55 
form the protein. In one embodiment of the invention, the 
compound is amine groups is cis-aconityl. This group adds to 
negative charges to each amine group and can be released at 
ph4.0. 
Examples for targeting strategies include synthesizing a 60 
heterobifunctional PEG that has a DNA binding domain at 
one end and another end that can attached to a protein. This 
PEG chain is then attached to a protein and then assembled 
into a preformed micelles that contains immunostimulatory 
DNA. Examples of DNA binding domains include acridine or 65 
polyacridines. Examples of targeting ligands include galac-
tose, mannose phosphate, mannose, peptides, and antibodies. 
Methods of Producing the Particles and Micelles of the Inven-
tion 
The invention provides methods for producing the particles 
of the invention. In one embodiment, the method comprises 
the steps of a) forming a hydrophobic polymer of a ketal and 
a dial or an unsaturated alcohol; b) forming a polymer particle 
of the polymer of a) in the presence of one or more active 
agents and thereby encapsulating the agent(s). Examples of 
suitable chemistries for forming the hydrophobic polymer of 
a ketal and a dial or an unsaturated alcohol include acetal 
exchange reaction using single or double emulsions and acy-
clic diene metathesis (Heffernan M J and Murthy N., 2005 
Bioconjug. Chem. 16(6):1340-2; Jain RA., 2000 Biomateri-
als. 21(23):2475-90; Wagener K. B. and Gomez F. J., 
"ADMET Polymerization", in Encyclopedia of Materials: 
Science and Technology, E. J. Kramer and C. Hawker, Edi-
tors, Elsevier, Oxford, 5, 48 (2002)). 
Suitable examples ofketals for this method include, but are 
not limited to, 2,2-dimethoxypropane, 2,2-dimethoxybutane, 
1, 1-dimethoxycyclohexane or dimethoxyacetophenole. Also 
in the scope of the invention are ketal polymers including 
aliphatic, cycloaliphatic or aromatic ketals containing one or 
more hetero-atom, such as nitrogen, sulfur, oxygen and 
halides. 
In accordance with the practice of the invention, the dial 
can be any of alkyl, aryl and cycloalkyl dials. 
Suitable examples of dials include, but are not limited to, 
1,4-benzenedimethanol, 1,4-cyclohexanedimethanol, 1,5-
pentane dial, 1,4-butane dial or 1,8-octane dial. 
In one embodiment, the invention provides a method for 
producing the particles of the invention comprising the steps 
of (a) forming PCADK polymer; and (b) forming a particle of 
PCADK in the presence of one or more active agents, thereby 
producing the particle of the invention. The PCADK polymer 
can optionally comprise a linker. 
In one embodiment, the invention provides a method for 
producing the particles of the invention comprising the steps 
of(a) forming PK!, PK2, PK3, PK4, PK5 and/or PK6 poly-
mer; and (b) forming a particle of one or more of PK!, PK2, 
PK3, PK4, PK5 and/or PK6 in the presence of one or more 
active agents, thereby producing the particle of the invention. 
The PK1-PK6 polymers can optionally comprise a linker. 
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The micelles can be produced in a two step process. First, 
the polymers of interest can be contacted with a liquid (polar 
or nonpolar liquid depending on the polymer to be used) 
under appropriate conditions so as to form a micelle. After 
micelle formation, the micelle can be crosslinked with an 
external crosslinking agent to produce the biodegradable 
micelle of the invention. 
Methods for Using the Compositions of the Invention 
The invention further provides methods for delivering the 
active agents of the invention, via the particles of the inven-
tion or the micelles of the invention, to a subject in order to, 
for example, deliver active agents so as to treat the subject 
suffering from a disease (e.g. alleviate symptoms associated 
with the disease) or disorder. The particles (e.g., made of 
PCADK, PK!, PK2, PK3, PK4, PK5 or PK6 polymer) or 
micelles may then be degraded or dissolved in the subject so 
as to release the active agent for delivery to the subject. The 
particles or micelles of the invention have variable degrada-
tion rates at various pH ranges and can be designed to release 
an active agent according to a desired profile. For example, 
particles formed from PK3 polymers would degrade and 
release an active agent faster than particles formed from PK6 
polymers. 
In one embodiment of the invention, the particles or 
micelles of the invention used for delivering active agents 
further comprise a linker. In a further embodiment, a particle 
formed of the PCADK polymer further comprises a linker 
(e.g., NTA) bound to an active agent is used for delivery of the 
active agent to a subject. 
The disease or disorder suffered by the subject can be any 
of HIV, malaria, TB, SARS, anthrax, Ebola, influenza, avian 
influenza and HCV. Further disease or disorder can be any of 
22 
The invention provides methods for regulating an immune 
response by administering active agents via the particles or 
micelles of the invention. In one embodiment of the inven-
tion, the particles or micelles used in the methods of the 
invention further comprise a linker. For example, in the meth-
ods of the invention, an immune response can be biased 
towards a Th immune response in a TLR-dependent manner 
by delivering or administering to a subject a particle or 
micelle of the invention containing a desired active agent. In 
10 one embodiment, a TLR-expressing cell is contacted with an 
agent (delivered by the particle or micelle of the invention) 
that effects a bias towards a Th immune response (e.g., a ThO, 
Th2 or T regulatory cell immune response). For example, the 
agent (e.g., a natural ligand, a biologically active fragment 
15 thereof, or a small or synthetic molecule) that activatesTLR-
2, ERK 1h, or c-fos. 
As noted above, the immune response can be regulated or 
modulated (e.g., increase biasing or decrease biasing toward 
a Th immune response) at a point in the signaling pathway 
20 downstream from receptor activation (e.g., downstream from 
TLR binding or downstream from TLR activation or recog-
nition). Thus, the patient can also be treated with an active 
agent or combination of active agents (delivered using the 
compositions of the invention) that bias the immune response 
25 by acting intracellularly on the elements of the downstream 
signaling pathway. 
The present invention provides methods for biasing 
towards a Th2 immune response by inducing cell signaling 
(e.g., activation) of any of the MAP kinase pathways, includ-
30 ing an ERK 1h pathway using a desired active agent delivered 
using the compositions of the invention. An induced MAP 
kinase pathway can be characterized by an increase in the 
amount and/or duration of phosphorylated components of the 
an infectious disease, autoimmune disease, allergic disease, 
disorder or complications associated with transplantation, 35 
diabetes and cancer. Examples of autoimmune disease 
include lupus, rheumatoid arthritis, psoriasis, asthma and 
COPD. 
MAP kinase pathways, including ERK 1h. 
In another embodiment of the methods of the invention, an 
active agent can be delivered, via the compositions of the 
invention, which modulates an ERK 1h MAP kinase pathway 
so as to regulate a TH2 immune response. In this embodi-
ment, as an example, an agonist of a TLR (e.g., TLR-2) The active agents are delivered through the particles of the 
invention by various administration means including, but not 
limited to, intravenous, subcutaneous, intramuscular, oral and 
inhalation means. The most effective mode of administration 
and dosage regimen forthe compositions of the present inven-
tion depends upon the exact location of the disease or disorder 
being treated, the severity and course of the disease or disor-
der, the subject's health and response to treatment and the 
judgment of the treating physician. Accordingly, the dosages 
of the molecules should be titrated to the individual subject. 
The interrelationship of dosages for animals of various 
sizes and species and humans based on mg/m2 of surface area 
is described by Freireich, E. J., et al. Cancer Chemother., Rep. 
50 (4):219-244 (1966). Adjustments in the dosage regimen 
maybe made to optimize the tumor cell growth inhibiting and 
killing response, e.g., doses may be divided and administered 
on a daily basis or the dose reduced proportionally depending 
upon the situation (e.g., several divided dose may be admin-
istered daily or proportionally reduced depending on the spe-
cific therapeutic situation). It would be clear that the dose of 
the compositions of the invention required to achieve treat-
ment may be further reduced with schedule optimization. 
As used herein, the term "subject" may include a human, 
any animal such as equine, porcine, bovine, murine, canine, 
feline, and avian subject, a cell or a cell tissue. In accordance 
with the practice of the invention the active agents can be 
delivered or administered to the subject (using the composi-
tions of the invention) before, after, or during the onset of the 
disease or disorder. 
40 induces phosphorylation of ERK 1h so as to enhance a TH2 
immune response. In yet another embodiment of the methods 
of the invention, an active agent can be delivered via the 
compositions of the invention so as to modulate a c-FOS 
pathway in the cell thereby regulating a TH2 immune 
45 response. In this embodiment, as an example, an agonist of a 
c-fos pathway induces expression of c-fos and/or phosphory-
lation of c-fos so as to enhance a TH2 immune response. 
Additionally, in yet a further embodiment of the methods of 
the invention, an active agent can be delivered via the com-
50 positions of the invention, so as to modulate a Th2 immune 
response by affecting TLR2 or its downstream signaling path-
way elements such as ERK 1h MAP kinase pathway and a 
c-FOS pathway. For example, the active agent, delivered via 
the compositions of the invention, can be used to modulate 
55 production or activity ofIL-10 (for example increase produc-
tion or upregulate ofIL-10). 
In one embodiment, the methods for biasing towards a Th2 
immune response includes decreasing or inhibiting signaling 
ofp38 and/or JNK pathway(s) which mediate (e.g., inhibit) 
60 IL12 production and thus biasing against a Thi response by 
administering an active agent delivered via the compositions 
of the invention. In another embodiment, the methods for 
biasing towards a Th2 immune response includes decreasing 
or inhibiting the amount of phosphorylated p38 and/or JNK, 
65 or decreasing or inhibiting the duration of phosphorylation of 
p38 and/or JNK which mediate (e.g., inhibit) IL12 production 
and thus biasing against a Thi response by administering 
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micelles or particles of the invention containing a desired 
active agent (or combination thereof). 
24 
The present invention also provides methods for biasing 
towards a Thi immune response by inducing cell signaling 
(e.g., activation) of any of the MAP kinase pathways, includ-
ing a p38 and/or JNK pathway by administering an active 
agent delivered via the compositions of the invention. An 
induced p38 and/or JNK pathway can be characterized by an 
increase in the amount and/or duration of phosphorylated 
components of the MAP kinase pathways, including p38, 10 
and/or JNK. 
with an active agent, delivered via the compositions of the 
invention, that inhibits biasing towards a Thi immune 
response. 
The following examples are presented to illustrate the 
present invention and to assist one of ordinary skill in making 
and using the same. The examples are not intended in any way 
to otherwise limit the scope of the invention. 
Advantages of the Invention 
Polyketal particles of the invention comprise, or are 
capable of encapsulating, a wide range of active agents, from 
small inhibitors to large proteins, and can be used to delivery 
the active agents to a subject suffering from a disease or 
condition or as a preventative measure. In one embodiment, the methods for biasing towards a Thi 
immune response includes decreasing or inhibiting signaling 
of ERK 1h and/or c-fos pathway( s) by administering an active 
agent delivered via the compositions of the invention. In 
another embodiment, the methods for biasing towards a Thi 
immune response includes decreasing or inhibiting the 
amount of phosphorylated ERK 1h and/or c-fos, or decreasing 
or inhibiting the duration of phosphorylation of ERK 1/2 and/ 
or c-fos by administering an active agent delivered via the 
compositions of the invention. 
Additionally, the invention provides methods for regulat-
ing a TH2 immune response which comprises contacting a T 
cell (e.g., a naive T cell) with a TLR-positive cell (such as a 
DC) treated in culture with a TLR agonist (e.g., TLR-2 ago-
nist), delivered via the compositions of the invention, which 
activates an ERK 1/2 pathway and/or which activates c-fos or 
c-fos pathway. 
Additionally, the invention provides methods for regulat-
ing a THI immune response which comprises contacting a T 
cell (e.g., a naive T cell) with a TLR-positive cell treated in 
culture with a TLR agonist (e.g., TLR-4 agonist), delivered 
via the compositions of the invention, which activates a p38 
pathway and/or a JNK pathway. 
The present invention provides methods for treating a sub-
ject having an immune-related condition or disease (e.g., 
allergies, autoimmune disease, and other immune-related 
conditions including cancer), comprising administering to 
the subject any of the agents of the invention, delivered via the 
compositions of the invention, in an amount effective to bias 
towards or against a Thi, Th2 or ThO immune response. The 
subject can be bovine, porcine, murine, equine, canine, feline, 
simian, human, ovine, piscine or avian. 
In one embodiment, a subject having a condition or disease 
associated with an exhuberant Th2 response is treated with an 
agent of the invention, delivered via the compositions of the 
invention, that activates cell signaling in the subject so as to 
bias towards a Thi immune response. Disease characterized 
by exhuberant Th2 response include, but are not limited to 
allergy, asthma, and chronic obstructive pulmonary disease 
(COPD (e.g., emphysema or chronic bronchitis). 
In another embodiment, a subject having a condition or 
disease associated with an exhuberant Th2 response is treated 
with a molecule that inhibits biasing towards a Th2 immune 
response, delivered via the compositions of the invention. 
In one embodiment, a subject having a condition or disease 
associated with an exuberant Thi response is treated with a 
agents of the invention, delivered via the compositions of the 
invention, that activates cell signaling in the subject so as to 
bias towards a Th2 immune response. Disease characterized 
by exhuberant Thi response include, but are not limited to 
diabetes, rheumatoid arthritis, multiple sclerosis, psoriasis, 
and systemic lupus erythematosis. 
In another embodiment, a subject having a condition or 
disease associated with an exuberant Thi response is treated 
In one embodiment, the active agents joined to or encap-
15 sulated by the polyketals can retain activity for several weeks 
in a subject. Additionally, the polyketals with the active 
agents can be freeze-dried, and are capable of being stored for 
months without degradation. The polyketals have a control-
lable degradation profile at various pH ranges, and if neces-
20 sary can be fine tuned for precision release of active agents. 
The polyketal polymer of the invention should overcome 
problems associated with administering active agents into a 
subject. For example, after administration of the active agent 
by injection, the blood supply in areas surrounding the injec-
25 tion site makes it highly likely that active agents will be 
immediately carried away following injection. The larger, 
micron-scale polyketals of the invention should overcome 
this obstacle and allow the polyketals comprising or encap-
sulating active agents to remain in the local microenviron-
30 ment. 
The polyketals of the invention have several unique prop-
erties that make them ideal as a delivery vehicle of active 
agents for the treatment of a disorder or disease (e.g., myo-
cardial treatment) or as a preventative measure: (1) they can 
35 degrade on a time scale that can be easily manipulated from 
1-2 days to weeks at a variety of pH values; (2) they can 
hydrolyze into neutral excretable compounds, and should 
therefore cause less degradation and denaturation of proteins 
than polyester-basedmicroparticles; (3) the polyketals can be 
40 solid particles and may be stable for extended periods after 
formulation; and ( 4) the properties of polyketals can be easily 
manipulated to alter particle size, shape and porosity. 
In one embodiment of the invention, altering the copoly-
mer percentage of the polyketals can change or fine tune the 
45 hydrolysis kinetics of the polyketals in order to provide con-
trollable release of active agents joined to or encapsulated by 
polyketals. For example, the monomer composition of PK4 
provides for faster hydrolysis kinetics than PK3 at pH 4.5. In 
turn, PK3 has faster hydrolysis kinetics than PK2 or PK5, 
50 while PK2 and PK5 have faster hydrolysis kinetics than PK! 
or PK6. Thus, active agents joined to PK4 will be released 
faster than active agents joined to PK3; active agents joined to 
PK3 will be released faster than active agents joined to PK2 or 
PK5; and active agents joined to PK2 or PK5 will be released 
55 faster than active agents joined to PK! or PK6. 
In another embodiment of the invention, the polyketals of 
the invention can be mixed in order to change or fine tune the 
release rate for active agents joined to or encapsulated by 
polyketals. For example, a polyketal with fast hydrolysis 
60 kinetics (e.g., PK4 or PK3) can be mixed with a polyketal 
with slower hydrolysis kinetics (e.g., PK! or PK6) and co-
administered to a subject. The active ingredient joined to PK4 
or PK3 will be released in a subject quickly to provide the 
subject with an immediate release (IR) dose of active agent, 
65 while the active agent joined to PK! or PK6 will be released 
at a slower rate allowing a gradual or extended release (ER) of 
the active agent in the subject. 
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Another advantage of the invention is that in one embodi-
ment, a linker can be attached to the polyketal polymer. The 
polyketal polymers may then be used to form particles or 
micelles with linkers. Particles or micelles with linkers allow 
dual delivery of one or more active agents to a subject, 5 
namely, via encapsulation of the active agents by the particle 
or micelle and attachment of the active agent to the particle or 
micelle to the linker. In one embodiment, this dual mode of 
delivery for active agents provides for dual release times for 
the active agents, with the linker bound active agents released 
10 
faster than the encapsulated active agents. 
The following examples are presented to illustrate the 
present invention and to assist one of ordinary skill in making 
and using the same. The examples are not intended in any way 
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of poly(l,4-phenylene acetone dimethylene ketal) (PPADK) 
dissolved in 500 µL of chloroform was added to 100 µL of 
FITC-Ova solution (-0.7 mg). This mixture was sonicated at 
40 watts for 1 minute to form the primary emulsion. Next, 5 
mL of0.2% w/v polyvinyl alcohol (PVA, Aldrich) in 10 mM 
pH 9 sodium phosphate buffer was added, and this mixture 
was sonicated at 40 watts for at least 1 minute to form the 
secondary emulsion. The emulsion was mixed under nitrogen 
ventilation for 4 hours, after which the volume was made up 
to 5 mL with buffer. Two batches of PKNs containing FITC-
Ova were prepared in this marmer, as well as two batches of 
plain PKN s (without FITC-Ova ). The PKN suspensions were 
stored at 4 ° C. 
Particle sizing was determined by dynamic light scattering to otherwise limit the scope of the invention. 
EXAMPLES 
Example 1 
15 (DLS). The two batches of FITC-Ovalbumin-loaded PKNs 
had effective diameters of 426 nm and 462 nm, and the empty 
PKN batches were 321 nm and 347 nm. 
Synthesis of Antigen Containing Crosslinked 
Micelles 
Crosslinked micelles that contain the protein antigen Oval-
bumin and immunostimulatory DNA were synthesized in a 
two step process. First, micelles were formed between the 
cationic block copolymer, PEG-polylysine-thiopyridal and 
negatively charged FITC-Ovalbumin (FITC-OVA) and 
immunostimulatory DNA (ISS-DNA). These micelles con-
tained a 10 mg/ml concentration of PEG-polylysine-thiopy-
ridal, a 0.5 mg/ml concentration of FITC-OVA and a 0.5 
mg/ml concentration of ISS-DNA. The micelles were 
allowed to form for one hour and were then crosslinked with 
0.4 mg/ml of dithio-ethylene glycol. The crosslinking reac-
tion was monitored by U.V. activity (342 nm), and indicated 
that the thiopyridal groups had been quantitatively reacted 
after 1 hour at room temperature. The encapsulation effi-
ciency ofFITC-OVA in the micelles was determined by cen-
trifuging the micelles through a 100 kD spin-filter ( centricon) 
and analyzing the recovered solution for FITC fluorescence 
(excitation 494 nm, emission 510 nm). This indicated that 
over 95% of the FITC-OVA was encapsulated in the micelles. 
Example 2 
Synthesis of Polyketal Particles (Single Emulsion 
Method for Delivery of Hydrophobic Drugs) 
Labeling of FITC-Ova 
Chicken egg albumin (ovalbumin) was labeled with fluo-
20 rescein as follows. Ovalbumin was dissolved at 10 mg/mL in 
200 mM pH 9 NaHC03 buffer. Fluorescein isothiocyanate 
(FITC) was dissolved at 10 mg/mL in DMSO. Next, 2.5 mL 
of ovalbumin solution (25 mg, 0.56 mmol) was mixed with 50 
µL ofFITC/DMSO (0.5 mg, 1.28 mmol) for at least 1 hour at 
25 30° C. The product was filtered in a Sephadex PD-10 column 
to remove the free dye; the column was loaded with 2.5 mL of 
product and was eluted with 2.5 mL water. The resulting 
ovalbumin concentration was approximately 7 mg/mL. The 
degree oflabeling was calculated to be 1.09 by measuring the 
30 absorbance ofFITC at 497 nm and using the estimated con-
centration of ovalbumin. 
Determination ofFITC-Ova encapsulation in PKNs 
The two FITC-Ova PKN batches were diluted by 5-fold in 
water, and a portion of each diluted sample was filtered 
35 through a 0.1 µm Supor syringe filter (Pall Acrodisc). The 
filtered and unfiltered samples were further diluted by 10-fold 
into pH 9 sodium phosphate buffer, and the fluorescence was 
measured with 494 nm excitation wavelength and 520 nm 
40 
emission wavelength. (FIG. 1) 
The encapsulation efficiency was calculated using the fluo-
rescence intensity of the filtered and unfiltered samples, as 
follows: 
45 EncapsulationEfficiency = Particles were synthesized with, poly(l,4-phenylene-ac-
etone dimethylene ketal) using an oil-in-water emulsion 
method. Briefly, 10 mg of 2, 1 mg of the ERK inhibitor 
UO 126 and 0.1 g of chloro-methyl fluorescein diacetate (CM-
FDA), weredissolvedin0.5mLofCHCl3 (with0.1 %triethy- 50 
!amine). This solution was then added to 5 mL of pH 9 buffer 
(10 mM NaHC03 ) containing 2 mg/ml polyvinyl alcohol 
(PVA, 31-50 kDa, Aldrich). The oil-water mixture was 
shaken briefly and then sonicated for 2 to 3 min at 40 watts 
(Branson Sonifier 250) to form a fine oil/water emulsion. The 
55 
emulsion was stirred under N2 flow for at least 3 h to evapo-
rate the solvent and produce a particle suspension. Particle 
sizes were analyzed by dynamic light scattering (DLS) and 
indicated that the average diameter was 282 nm. 
1 - --- x 100% = 1 - -- x 100% = 60% ( 
Filtered ) ( 189 .5) 
Unfiltered 476.7 
Example 4 
Synthesis and Degradation ofKetal-Backbone 
Polymer (Polyketal) 
FIG. 2 shows: (A) Ketal exchange reaction between 1,4-
benzenedimethanol and 2,2-dimethoxypropane to produce 
the ketal intermediate 1. (B) Stepwise polymerization of 1 to 
produce polyketal 2. Reaction steps A and B are driven for-
Example 3 
Synthesis of Polyketal Particles Encapsulating 
Ovalbumin (Double Emulsion Method for Synthesis 
of Hydrophilic Drugs) 
Polyketal particles (PKNs) containing FITC-ovalbumin 
were fabricated using a double emulsion method. First, 20 mg 
60 ward by distilling off the methanol byproduct. (C) Formation 
of drug-loaded particles by the solvent evaporation method. 
Particles exhibit pH-sensitive degradation into low molecular 
weight excretable compounds. 
65 
Synthesis 
The Polyketals are synthesized via a new polymerization 
strategy based on the ketal exchange reaction (14). This reac-
tion is generally used to introduce protecting groups onto low 
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molecular weight alcohols and has not been used previously 
to synthesize polymers. However, we demonstrate here that 
the ketal exchange reaction can be used to synthesize an acid 
sensitive polymer by simply reacting 2,2-dimethoxypropane 
(DMP) with a dial. We propose that the polymerization 5 
occurs through the reaction mechanism in FIG. 2. The ketal 
exchange reaction is an equilibrium reaction involving pro-
tonation ofDMP followed by nucleophilic attack by the alco-
hol. This equilibrium is shifted toward formation of the ketal 
intermediate 1 by distilling off the methanol byproduct. As 10 
the reaction proceeds, molecules of 1 combine in a stepwise 
manner to form polyketal 2. 
A representative polymerization ofDMP and 1,4-benzene-
dimethanol (BDM) gave the polyketal 2 with a 48% yield. 
15 
The polymerization was carried out in a 25 mL two-necked 
flask connected to a short-path distilling head. BDM (1.0 g, 
28 
dependent on the size of the particles and we would expect 
smaller particles to have greater pH sensitivity than ground 
particles. 
Example 5 
Synthesis of Micron Sized Particles 
Compound 2 (from Example 4, supra) was also used to 
synthesize micron sized particles. An oil-in-water emulsion 
method (Panyam, J.; Williams, D.; Dash, A.; Leslie-Pelecky, 
D.; Labhasetwar, V. J. Pharm. Sci. 2004, 93, 1804-1814) was 
used to form the particles. 
Briefly, 50 mg of 2 dissolved in 1 mL CHCl3 (with 0.1 % 
triethylamine) was added to 5 mL of 10 mM NaHC03 pH 9 
buffer containing various amounts of polyvinyl alcohol 
(PVA, 31-50 kDa, Aldrich) as the emulsifier. The oil-water 
mixture was shaken briefly and then sonicated for 2 to 3 min 
at 40 watts (Branson Sonifier 250) to form a fine oil/water 
emulsion. The emulsion was stirred under N 2 flow for at least 
3 h to evaporate the solvent and produce a particle suspension. 
Particle sizes were analyzed by dynamic light scattering 
(DLS) and SEM. DLS samples were prepared by diluting the 
particle suspension in 10 mL pH 9 buffer and allowing the 
larger particles to settle out. An aliquot from the liquid portion 
of each vial was then diluted for DLS particle sizing 
(Brookhaven 90Plus particle sizer). An SEM sample was 
made with the 0.2:1 ratio of PVA:polyketal by centrifuging 
the particle suspension for 10 min (5000 g, 4° C.), washing 
7.3 mmol, Aldrich) dissolved in 10 mL warm ethyl acetate 
was added to 10 mL distilled benzene kept at 100° C. Re-
crystallized p-toluene sulfonic acid (5.5 mg, 0.029 mmol, 20 
Aldrich) dissolved in 550 µL ethyl acetate was then added. 
After allowing the ethyl acetate to distill off, distilled DMP 
(900 µL, 7.4 mmol, Aldrich) was added to initiate the reac-
tion. Additional doses of DMP were added via a metering 
funnel, with each dose consisting of2 mL benzene plus 300 to 25 
500 µL DMP. Each dose was added over a 30 to 40 min period 
with a 30 min interval in between. The total duration of the 
reaction was 7 h. The reaction was stopped with the addition 
ofl 00 µL triethylamine and was precipitated in cold hexanes. 
The crude product was vacuum filtered, rinsed with ether and 
hexanes, and vacuum dried to yield 600 mg of white solid 
product ( 48% yield). The recovered polymer was analyzed by 
GPC and 1 H NMR. 
30 with distilled water, and lyophilizing the recovered pellet. 
FIG. 3A shows the GPC trace from one batch in which 
35 
Mw =4000 was obtained, corresponding to a degree of poly-
merization of 22.5 repeating units, with a polydispersity 
indexofl.54. The 1HNMR spectrum(FIG. 3B) confirms that 
the repeating unit of2 contains a dimethyl ketal group ('6a'). 
Together, the GPC and 1 H NMR data provide evidence for the 40 
successful synthesis of polyketal 2. 
Hydrolysis 
The hydrolysis kinetics of 2 were measured at pH values 
corresponding to lysosomes (pH 5.0) and the bloodstream 
(pH 7.4). The hydrolysis rates were measured by grinding 45 
polyketal 2 into a fine powder and adding it to deuterated 
solutions at pH 7.4 (phosphate buffer), pH 5.0 (acetate 
buffer), and pH 1.0 (DC!). The suspensions were stirredat37° 
C. and data points were taken at 3 h, 24 h, 48 h, and 72 h. Each 
suspension was centrifuged for 4 min at 1800 g, and the 50 
supernatant was analyzed by 1 H NMR. The spectra contained 
peaks for BDM (7.24 and 4.47 ppm) and acetone (2.05 ppm). 
The average of the two BDM peak integrals was used to 
determine the relative degree of hydrolysis. The percent 
hydrolysis was calculated as the BDM peak average of the pH 55 
7.4 or 5.0 sample divided by the BDMpeakaverageofthepH 
1.0 control batch. 
As expected, the particle size was sensitive to the ratio of 
PVA to polyketal. The DLS particle diameters were 520 nm, 
290 nm, and280nm for samples containing 0.2:1, 0.8:1, and 
2: 1 ratios of PV A:polyketal, respectively. The SEM images of 
the 0.2: 1 batch (FIGS. SA and SB) confirm that the polyketal 
does form micron sized particles, with particle size distribu-
tion ranging from 0.5 to 30 µmin diameter. 
Example 6 
Synthesis and Characterization of Micelles and 
Polyketal Particles 
Materials and Methods 
Encapsulation of Dexamethasone in Polyketal Particle 
The anti-inflammatory drug dexamethasone (Dex, Sigma) 
was encapsulated into particles made with polyketal 2. Dex-
loaded particles were formulated using the same procedure as 
that described above, except that the oil phase contained a 5 
mg/ml concentration of Dex and a 1: 1 ratio of PVA:polyketal 
was used. SEM images of these particles demonstrate that 
they are 200-600 nm in diameter (FIG. SC). Particle sizing by 
DLS indicated an effective diameter of 250 nm for the Dex-
loaded particle batches. The Dex encapsulation efficiency 
ranged between 43-53%. Control batches were prepared with 
polyketal/PVA only and Dex only. To measure Dex encapsu-
lation, each particle batch was re-suspended in pH 9 buffer, 
and an aliquot was then further diluted. A portion was filtered 
through a 0.1 Om Supor membrane Acrodisc syringe filter 
Exponential decay half-lives were calculated to be 102 hat 
pH 7.4 and 35 hat pH 5.0, representing a 3-fold rate increase 
from pH 7.4 to 5.0 (FIG. 4). The pH sensitivity of2 is signifi-
cantly less than that reported by Kwon, et al. (Kwon, Y. J.; 
Standley, S. M.; Goodwin, A. P.; Gillies, E. R.; Frechet, J.M. 
J. Mal. Pharm. 2005, 2, 83-91) for a water-soluble ketal. We 
hypothesize that the lower pH sensitivity of 2 is due to its 
water insolubility, which limits the diffusion of water and 
creates another rate limiting step that is insensitive to pH. The 
diffusion kinetics of water into materials made of 2 will be 
60 (Pall Corp.), and the 242 nm absorbance of the filtrate was 
recorded with a Shimadzu UV-1700 spectrophotometer. The 
encapsulation efficiency was calculated as (Anex-ADexPoly)/ 
(ADex-APoly), where A is the absorbance at 242 nm and the 
subscripts 'Poly', 'Dex', and 'DexPoly' refer to the 
65 'Polyketal only', 'Dex only', and 'Dex+Polyketal' samples, 
respectively. These calculations resulted in a Dex encapsula-
tion efficiency of 43% to 53% for various samples. 
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Micelle Formation 
FIG. 8 is a schematic representation showing peptide 
crosslinked micelle design and synthesis. Step I: ISS DNA 
and I are mixed to form micelles (uncrosslinked micelle). 
Step 2: These micelles are then crosslinked with the antigenic 5 
peptide (II) to generate a delivery system that can encapsulate 
both immunostimulatory molecules and peptide antigens. 
After phagocytosis by APCs, the peptide-crosslinked 
micelles release their components. 
An HIV peptide vaccine was synthesized using the PCM 10 
strategy with the peptide CGCRIQRGPGRAFVTIGKCGCG 
(II)(SEQ ID N0:4). The peptide II comes from the GP-120 
protein and contains the sequence RIQRGPGRAFVTIGK 
(SEQ ID N0:5), which is both a class I and II antigen. First, 15 
micelles were formed between I and ISS-DNA by mixing 0.5 
mg ofl with 0.1 mg ofISS DNA (5-TCCATGACGTTCCT-
GACGTT-3)(SEQ ID N0:6)(charge ratio was I to 15 (-/+)) 
30 
nm (representing the released thiopyridone). The percent of 
cysteine groups reacted was determined by the following 
formula: 
ABS1 -ABS2 
reacted peptide(%) = x 100% 
ABS0 
where: ABS1 =UV absorption at 342 nm for the peptide-
crosslinked micelles reaction (filled circles); ABS2=UV 
absorption at 342 nm for the uncrosslinked micelles, without 
peptide (empty squares); ABS
0
=UV absorption at 342 nm 
when all of the thiopyridone groups have been reacted (by 
addition ofDTT) (empty circles). 
FIG. 10 shows the effects of GSH on release of peptides 
and DNA.A. GSH sensitive peptide release. The stimuli 
responsive release of peptides from the PCMs due to the 
presence ofGSH was investigated to determine ifthe PCMs 
will release peptide antigens after phagocytosis. The PCMs 
were incubated with different concentrations of GSH, for 24 
hours in 50 mM pH 7.4 PBS buffer, and then analyzed by 
HPLC to determine the release of peptides. This figure dem-
onstrates that the release of peptides is triggered by the pres-
in 0.5 ml of 50 mM PBS. Dynamic light scattering of these 
micelles using the Cumulants method indicated that they had 20 
an average diameter of 57 .0 nm. These micelles were then 
crosslinked by adding 0.1 mg of II to the micelles (equal 
molar ratio of cysteines on II to thiopyridal groups on I). The 
peptide II was incorporated into the micelles through a dis-
ulfide exchange reaction. 25 ence of GSH. Incubation of the PCMs with I 0 mM GSH 
FIG. 9 shows synthesis and characterization of PEG-polyl-
ysine thiopyridal. A. Synthesis of PEG-polylysine thiopyridal 
(I). 44 µmole of PEG-Poly-I-lysine (with PEG=5 kd and 
Poly-l-lysine=5,000) was dissolved in I ml ofDMF, in a 5 ml 
round bottom flask, fitted with a stir bar (overnight stirring at 30 
room temperature was required to completely dissolve the 
polymer). 415 µmole of hydroxyl-ethyl thiopyridal acrylate 
and 58 µl oftriethylamine were then added to the PEG-poly-
1-lysine solution and the reaction was allowed to run for 24 
35 
hours at room temperature. The product was isolated by pre-
cipitating the reaction solution into 15 ml of ice cold diethyl 
ether. The yield was 88.2%. B. 1H-NMR spectrum of PEG-
PLL-thiopyridal in D20. The product of A) was analyzed by 
1H NMR in D20. The percentage of amines alkylated was 40 
determined by comparing the peak intensity ratio of pyridine 
protons (-NC5H4 : o=7.IOI ppm, 7.629 ppm, 8.187 ppm) 
versus a, ~' y-methylene protons of poly-I-lysine 
(--CH2CH2 CH2 : o=l.122 ppm, 1.285 ppm, 1.553 ppm), this 
indicated that a 100% of the amines had been reacted. C./D. 45 
(intracellular levels) induces the release of 71 % of peptide, 
whereas incubation of the PCMs with just buffer causes the 
release of only 10% of peptides. B. GSH sensitive DNA 
release. The ability of the PCMs to protect encapsulated ISS-
DNA from degradation by serum nucleases was investigated. 
PCMs were synthesized (as described above) and incubated 
with 10% serum for 12 hours, these PCMs were then exam-
ined by gel electrophoresis to determine the stability of the 
encapsulated ISS-DNA. As a control, ISS-DNA by itself was 
incubated with serum. This figure demonstrates that ISS-
DNA, by itself, is completely hydrolyzed in I 0% serum (Lane 
2), in contrast ISS-DNA encapsulated in the PCMs is pro-
tected from serum nucleases, presumably because of the 
effects of the crosslinking (Lane 3), which should prevent 
nucleases from entering the micelle. C. ISS-DNA is protected 
from serum nucleases in the PCMs. A key advantage of the 
PCM strategy is that it generates a crosslinked delivery sys-
tem. This crosslinking should stabilize the PCMs in vivo. The 
stability of the PCMs to decomposition was investigated by 
mixing the negatively charged polymer, poly(vinyl sulfate) 
(PVS) with the PCMs, this mixture was then analyzed by gel 
electrophoresis to determine the quantity of ISS-DNA dis-
placed by the PVS. As a control, PVS was also incubated with 
uncrosslinked micelles that were just composed of II and 
Dynamic light scattering analysis of PCMs uncross-linked 
(C) and peptide cross-linked (D). A 50 mM PBS buffer solu-
tion, at pH 7.4, containing 0.06 mg/ml of PEG-polylysine 
thiopyridal and 20 µg/ml of ISS DNA was made and filtered 
through a 200 nm syringe filter. This solution was then ana-
lyzed by dynamic light scattering (Zetasizer Nano ZS, Mal-
vern Instruments), using the Cumulant method ( C). This solu-
tion was then crosslinked by adding 0.12 mg of peptide 
antigen (II), after 3 hours of reaction the solution was ana-
lyzed by DLS as described above, the size and the size dis-
tribution of the crosslinked micelles are shown in D). E. 
Crosslinking reaction of cysteines on peptide anigen (II). F. 
UV analysis of crosslinking reaction between peptide anigen 
(II) and block copolymer micelles. Block copolymer micelles 
were formed between I and ISS DNA by mixing 0.5 mg ofl 
with 0.1 mg ofISS DNA (representing a 15/1 amine to phos-
phate ratio), in0.5 ml of50mMNaH2P04 buffer (pH 7.4), in 
50 ISS-DNA. Figure A, lane 4, demonstrates that PVS can dis-
rupt uncrosslinked micelles that are just composed of ISS-
DNA and II. In contrast, A, lane 5 demonstrates that PVS 
cannot displace ISS-DNA from the PCMs, presumably 
because the peptide crosslinking prevents the PVS from dif-
55 fusing into the micelles and displacing the ISS-DNA. Impor-
tantly, after incubation of the PCMs with intracellular con-
centrations of GSH, the PCMs release encapsulated ISS-
DNA, in the presence of PVS, demonstrating that the micelles 
should release their contents after phagocytosis. (lanes 2 and 
60 3 in b) ). Charge ratio ofISS-DNA to I is I to 15 (-/ + ); I µg of 
DNA was loaded in each lane; GSH (100 µM) was added to 
lane 3 to induce release of encapsulated ISS-DNA. All 
samples were incubated with I 0% serum at room temperature 
for 12 h. 
an eppendeorf tube. After incubation for 2 hours at room 
temperature, 0. I mg of II (representing a 1: I cysteine to 
thiopyridal ratio) was added to the micelles. The crosslinking 65 
reaction between the cysteines on II with the thiopyridal 
groups in the micelles was determined by UV analysis at 342 
FIG. 11 depicts block copolymer micelles: A. Chemical 
structure of PEG-poly(Lysine-Thio-Pyridyl). PEG chain 
gives stability to the micelles, Polylysine segment is used for 
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electrostatic interactions with proteins and DNA or RNA. 
Thiopyridal group is for subsequent crosslinking via a disul-
fide bond. B. Step 1: Mix PEG-poly(Lysine-thio-pyridal) 
with DNA and protein, form micelles, with PEG on the out-
side. C. Step 11: Crosslink micelles with a di-thiol containing 5 
molecule, such as di-thioethylene glycol. D. Crosslinked 
micelles are reduced by Glutathione, which has a much 
higher concentration in the cell than in the blood. 
FIG. 12 shows the immunology of micelles. A. Uptake of 
SIINFEKL-CFSE (SEQ ID NO: 1) micelles by human mono- 10 
cyte derived DCs. Human PBMC derived DCs (day 6 of 
culture) were pulsed with SIINFEKL/CFSE (SEQ ID NO: 1) 
micelles for 4h in 37° C. at the concentration of 10 µg/ml, 
5x10*5 cell/well, 96-U wells, RPMI/10% FCS. Cells were 
washed, fixed on the figures and prepared for confocal micro- 15 
scope imaging. B. Efficient uptake of micelle encapsulated 
SIINFEKL peptide (SEQ ID NO: 1) by human monocyte 
derived DCs. Human PBMC derived DCs (day 6 of culture) 
were pulsed with SIINFEKL/CFSE (SEQ ID NO: 1) plain (1) 
or micelle formulated (2,3) for 4h in 37° C. at the concentra- 20 
tion of 10 µg/ml, 5x10*5 cell/well, 96-U wells, RPMI/10% 
FCS. Cells were washed, stained for CD! le and HLADR. 
Cells were gated for CD! le+, HLADR+ cells and analysed 
for CFSE fluorescence. C. Efficient uptake of micelle encap-
sulated SIINFEKL peptide (SEQ ID NO: 1) by mouse DCs 25 
and Macrophages. Total mouse C57Bl/6J FLT3-L spleno-
cytes were pulsed with 1 or 10 µg/ml of CFSE labeled plain 
SIINFEKL (SEQ ID NO: 1 )(1) or micelle formulated peptide 
(2,3) for 4 hours (blue line), or remained untreated (red line) 
at 37° C. at the concentration lx10*6 cell/well, 96-U wells, 30 
RPMI/10% FCS. Cells were stained for CD! le and CD! lb 
and analyzed for CFSE positive fluorescence. 
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96-U wells, RPMI/10% FCS. Cells were stained for CD! le 
and CD 11 b and analyzed for CMFDA positive fluorescence. 
Data represent medium treated cells (shaded line) or 5 hours 
uptake (black line). 
FIG. 16 is a schematic diagram showing the experimental 
outline for T cell stimulation in-vitro using OVA-OT/1 trans-
genic model. 
FIG. 17 shows the immunology of micelles. A. Micelle 
formulated antigen induces potent T cell responses in-vitro. 
Purified CD! le+ cells from a syngeneic C57Bl/6J H-26 
mouse were pulsed for 4 hours with indicated concentrations 
and combinations of ovalbumin and CpG plain or micelle 
formulated. Cells were washed and lx10*5 ofCDl lc+were 
cocultured with lx10*6 of total OT-1 (SIINFEKL (SEQ ID 
NO: 1 )specific) splenocytes for 5 days. After 5 days cells were 
restimulated with a SIINFEKL peptide (SEQ ID NO: 1 )(1 
ug/ml) with BFA (5 ug/ml) for 6 hours and stained for CDS 
and intracellular IFNy. Left panel represents the Flow Cytom-
eter analysis; right panel shows the summary of the data. B. 
Micelle formulated antigens overcome CD4+ dependent 
mechanisms of CDS+ T cells induction. Purified CD! le+ 
cells from a syngeneic C57B 1/6J H-26 mouse were pulsed for 
4 hours with indicated concentrations and combinations of 
ovalbumin and CpG plain or micelle formulated. Cells were 
washed and lx10*5 ofCDl lc were cocultured with 5x10*5 
of CDS+ MACS purified OT-1 splenocytes (purity of -90%) 
for 5 days. After 5 days cells were restimulated with a SIIN-
FEKL peptide (SEQ ID NO:l)(l ug/ml) with BFA (5 ug/ml) 
for 6 hours and stained for CDS and intracellular IFNy. Left 
panel represents the Flow Cytometer analysis; right panel 
shows the summary of the data. C. Micelle formulated anti-
gen activate DCs in-vivo. C57Bl/6J mice (2/group) were 
injected i.v. with 5 µg/mouse of ovalbumin/CpG as plain or 
micelle formulated in 500 ul PBS. Spleens were harvested at 
35 4 and 24 hours post injection, treated with collagenase (30 
min/37 C), homogenized, and treated with erythrocyte lysis 
buffer. CD l lc+ cells were stained for CDSO or CDS6 markers 
and analyzed with a flow cytometer. Data represent isotype 
FIG. 13 is a bar graph showing that micelle formulated 
SIINFEKL peptide (SEQ ID NO: 1) induces potent T cell 
responses in-vitro. Purified CD! le+ cells from a syngeneic 
C57Bl/6J H-26 FLT3-L treated mouse were pulsed for 4 
hours with indicated concentrations and combinations of 
plain or micelle formulated SIINFEKL peptide (SEQID 
NO:l). Cells were washed and cocultured with total OT-1 
splenocytes for 20h (left panel) or 96h (right panel). Cells 40 
were stained for CDS and intracellular IFNy and analyzed on 
a flow cytometer. Graphs represent: micelle SIINFEKL (SEQ 
control (shaded), nontreated mouse (grey line) or antigen 
injected mouse (black line). 
FIG. 18 shows the immunology of micelles and polyketal 
particles. A. Micelle formulated vaccines induce strong T cell 
responses in-vivo-CDS+ IFNy+. Cohorts of 4 C57Bl/6J 
mice were vaccinated s.c. with 5 µg/mouse of OVA (1) or 
ID N0:1)213.3 (black bar), micelle SIINFEKL (SEQ ID 
NO:l) 213.2 (grey bar), plain SIINFEKL (SEQ ID NO:l) 
(empty bar), medium (dotted bar) stimulated CDllc+DCs. 45 OVA+CpG (2), micelle OVA (3), micelle OVA/CpG ( 4). Ani-
mals were boosted at day 36 (BOOST 1) and S4 (BOOST 2) 
using the same antigen formulations. Blood was harvested at 
days 6 post BOOST 2 and PBMCs were isolated using His-
FIG. 14 shows the immunology of micelles. A. Efficient 
uptake ofmicelle encapsulated OVA protein by mouse DCs 
and Macrophages. Total mouse C57Bl/6J FLT3-L spleno-
cytes were pulsed with 1 or 10 µg/ml of FITC labeled plain 
ovalbumin (1) or micelle formulated protein (2) for 1 hour 50 
(black line), 5 hours (dotted line) or remained untreated 
(shaded). 37° C. at the concentration lx10*6 cell/well, 96-U 
wells, RPMI/10% FCS. Cells were stained for CDllc and 
CDllb and analyzed for FITC positive fluorescence. B. 
Micelle encapsulated OVA/CpG activates DCs in-vitro. Total 55 
mouse C57Bl/6J FLT3-L splenocytes were pulsed with 1 
µg/ml of plain OVA (!)plain OVA+l ug ofCpG (2) ormicelle 
formulated OVA (3) or micelle OVA+l ug ofCpG (4) for 24 
hours. CDllc+ cells were analysed for and CDSO or CDS6 
markers. Data represent isotype control (shaded), untreated 60 
(grey line) or stimuli treated (black line) cells. 
FIG. 15 is a graph depicting the immunology of polyketal 
particles. Uptake of polyketal particle (PKN) encapsulated 
U0126 by mouse DCs and Macrophages in-vitro. Total 
mouse C57Bl/6J FLT3-L splenocytes were pulsed with 1 or 65 
10 µg/ml of CMFDA labeled Polyketal Particle carrying 
U0126 ERK inhibitor for 5 hours at 37° C., lx10*6 cell/well, 
topaque gradient method, and restimulated with SIINFEKL 
peptide (SEQ ID NO:l) (1 ug/ml) and BFA (5 ug/ml) for 6 
hours and stained for CDS and intracellular IFNy. Left panel 
represents the Flow Cytometry analysis and gating strategy 
for selected mice; right panel shows the s=ary of the data 
as a% of CDS+ IFNy+ cells of total CDS+ T cells. B. Micelle 
formulated vaccines induce strong T cell responses in-vivo-
CDS+ TNFa+. Cohorts of 4 C57Bl/6J mice were vaccinated 
s.c. with 5 µg/mouse of OVA (1) or OVA+CpG (2), micelle 
OVA (3), micelle OVA/CpG (4) micelle. Animals were 
boosted at day 36 (BOOST 1) and S4 (BOOST 2) using the 
same antigen formulations. Blood was harvested at days 6 
post BOOST 2 and PBMCs were isolated using Histopaque 
gradient method. PBMCs from 4 mice were pooled and 
restimulated with SIINFEKL peptide (SEQ ID NO: 1 )(1 
ug/ml) andBFA (5 ug/ml) for6 hours and stained for CDS and 
intracellular TNF a and IL-10. Left panel represents the Flow 
Cytometer analysis and gating strategy for selected mice; 
right panel shows the summary of the data as a % of CDS+ 
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TNFa+ cells of total CDS+ T cells. C. Kinetics of specific 
CDS+/IFNy+ T cells after OVA/CpG vaccination. Cohorts of 
4 C57Bl/6J mice were vaccinated s.c. with 5 µg/mouse of 
OVA+CpG (grey line) and micelle OVA/CpG (blue line). 
Animals were primed at day 0 and boosted at day 36 (BOOST 5 
1) and S4 (BOOST 2) using the same antigen formulations. 
Blood was harvested at distinct days post priming and boosts 
and PBMCs were isolated using Histopaque gradient method. 
PBMCs from 4 mice were restimulated with SIINFEKL pep-
tide (SEQ ID NO:l)(l ug/ml) and BFA (5 ug/ml) for 6 hours 10 
and stained for CDS and intracellular IFNy. Panels represent 
the summary of the data as % of CDS+ IFNy+ cells of total 
CDS+ T cells including SEM error bars. D. Kinetics of spe-
cific CDS+/IFNy+ T cells after OVA+U0126 PKN vaccina-
15 
tion. Cohorts of 4 C57Bl/6J mice were vaccinated s.c. with 5 
µg/mouse of OVA (grey line) micelle OVA (blue line) and 
micelle OVA+lO ug U0126 PKN(red line). Animals were 
primed at day 0 and boosted at day 36 (BOOST 1) and S4 
(BOOST 2) using the same antigen formulations. Blood was 20 
harvested at distinct days post priming and boosts and 
PBMCs were isolated using Histopaque gradient method. 
PBMCs from 4 mice were restimulated with SIINFEKL pep-
tide (SEQ ID NO:l)(l ug/ml) and BFA (5 ug/ml) for 6 hours 
and stained for CDS and intracellular IFNy. Panels represent 25 
the summary of the data as % of CDS+ IFNy+ cells of total 
CDS+ T cells including SEM error bars. E. Micelle formu-
lated vaccines induce strong antigen specific IgG antibody 
response in-vivo. Cohorts of 4 C57Bl/6J mice were vacci-
nated s.c. with 5 µg/mouse of OVA (1) or OVA+CpG (2), 30 
micelle OVA (3), micelle OVA/CpG (4) micelle OVA+lO ug 
of PKN U0126 (5) or micelle OVA/CpG+lO ug of PKN 
U0126 (6).Animals were boosted at days 36 and S4 using the 
same antigen formulations. Bleedings were performed at 
35 
week 4 post priming (PRIME), week 6 post 1 s'boost (BOOST 
1) and week 7 post rd boost (BOOST 2). Sera from indi-
vidual mice were pooled and tested for OVA specific IgG 
total, IgGl, IgG2a and IgG2b antibody reactivity using plate 
ELISA. Antibody reactivity was measured in 450 nm absor- 40 
bance of serum serial dilution. Data are represented as a 
reciprocal of specific anti-OVA antibody. F. Micelle formu-
lated vaccines induce antigen specific IgE and IgM antibody 
response in-vivo. Cohorts of 4 C57Bl/6J mice were vacci-
nated s.c. with 5 µg/mouse of OVA (1) or OVA+CpG (2), 45 
micelle OVA (3), micelle OVA/CpG (4) micelle OVA+lO ug 
of PKN U0126 (5) or micelle OVA/CpG+lO ug of PKN 
U0126 (6).Animals were boosted at days 36 and S4 using the 
same antigen formulations. Bleeding was performed and 
week 7 post rd boost. Sera from individual mice were pooled 50 
and tested for OVA specific IgE and IgM antibody reactivity 
using plate ELISA. Antibody reactivity was measured in 450 
nm absorbance of serum serial dilution. Data are represented 
as a reciprocal of specific anti-OVA antibody. 
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FIG. 20 shows SEM images depicting that particles from 
PCADK can encapsulate the hydrophobic compounds and 
drugs such as rhodhamine red and ebselen. 
FIG. 21 shows line graphs showing that release of 
rhodhamine red from PCADK is pH sensitive. 
Synthesis and Characterization of Polyketals and Particles 
Thereof 
FIG. 6 is a schematic representation showing the steps of 
particle formation. A. Step 1: Dissolve polyketal and drug 
into chloroform; dissolve polyvinyl alcohol in water. B. Step 
2: Add chloroform solution to water and sonicate, generate 
micron sized droplets. Step 3: Let chloroform evaoporate, 
generates particles. P FIG. 7 shows polyketal particles loaded 
with Fluorescein are taken up in the liver. Murine liver tissue 
slice showing release of fluorescein from PKNs following 
intravenous injection. 
FIG. 22 is a chemical representation showing that polyket-
als with almost any aliphatic dial can be made. The hydro-
phobicity of the polyketal determines its hydrolysis kinetics. 
FIG. 23 is a photograph showing that FITC labeled 
polyketals are phagocytosed by liver macrophages. Phagocy-
tosis of PKNs in vivo by Kupffer cells. Mice were injected 
with either FITC-PKNs or Empty PKNs. The livers of these 
mice were analyzed by histology. Left: FITC-PKNs are abun-
dantly present in Kupffer cells, as evidenced by the punctate 
green fluorescence (1 OOx magnification). Middle: empty 
PKN s generate very little background green fluorescence 
(lOOx magnification). Right: immunohistochemistry (IHC) 
for FITC (red) confirms uptake by Kupffer cells ( 400x mag-
nification). 
FIG. 24. A. Double emulsion procedure used to encapsu-
late catalase and super oxide dismutase in polyketal particles. 
A 50 µL aqueous solution of catalase (1 mg/ml) was dispersed 
into an organic phase, consisting of 75 mg of PCADK, dis-
solved in 1 mL of dichloromethane, using a homogenizer, 
generating a water in oil (w/o) emulsion. This w/o emulsion 
was then dripped into 25 mL of a 4% PVA solution, which was 
mechanically stirred with a homogenizer. The resulting 
w/o/w emulsion was then poured into 225 mL of a 4% PVA 
solution and mechanically stirred for several hours until the 
methylene chloride evaporated. The resulting particles were 
isolated by centrifugation, freeze-dried and examined by 
SEM (B) The protein encapsulation efficiency was 35%. The 
CAT-PKNs have an average diameter of approximately S 
microns. B. SEM image of catalase containing particles, and 
fluorescent microscope images of catalase containing par-
ticles. C. Catalase particles have enzymatic activity, as evi-
denced by their ability to decrease the absorbance at 240 nm 
of hydrogen peroxide. 
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Example 7 
Synthesis of Polyketal Copolymers and Formation of 
Particles 
In this example a strategy is presented for manipulating the 
hydrolysis kinetics of poly( cyclohexane-1,4-diyl acetone 
dimethylene ketal) (PCADK) by controlling its hydrophilic-
ity through copolymerization with other dials, of varying 
hydrophilicity. Six polyketal copolymers PKl to PK6, based 
on PCADK, were synthesized. 
Materials and Methods 
Polyketal copolymers were synthesized in a 25 mL two-
necked flask, connected to a short-path distilling head. The 
dials, 1,4-cyclohexanedimethanol (1.04 g, 7.25 mmol) and, 
either 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, or 
1,S-octanediol were dissolved in 20 mL of distilled benzene 
and kept at 100° C. Re-crystallized p-toluenesulfonic acid 
(5.5 mg, 0.029 mmol), dissolved in 550 µL of ethyl acetate, 
was added to the benzene solution. The ethyl acetate was 
distilled off, and distilled 2,2-dimethoxypropane (equal 
molar quantity as the two dials combined) was added to 
initiate the reaction. Additional doses of 2,2-dimethoxypro-
pane (500 µL) and benzene (2 mL) were subsequently added 
36 
PK4. 1H NMR (CDC13 ) o=3.4-3.1S (m, 4H), 1.6S (s, 2H), 
1.S5-0.93 (m, SH), and 1.32 (s, 6H). 
PK5. 1H NMR (CDC13 ) o=3.4-3.1S (m, 4H), 1.67 (s, 1.SH), 
1.S5-0.93 (m, SH), and 1.32 (s, 6H). 
5 PK6. 1H NMR (CDC13 ) o=3.4-3.1S (m, 4H), 1.6S (s, 1.SH), 
1.S5-0.93 (m, SH), and 1.32 (s, 6H). 
The molecular weight of the polyketal copolymers was 
determined by gel permeation chromatography (GPC) using 
10 
a Shimadzu system (Kyoto, Japan) equipped with a UV 
detector. THF was used as the mobile phase at a flow rate of 
1 mL/min. Polystyrene standards (Peak Mw= 1060, 2970, and 
106SO) from Polymer Laboratories (Amherst, Mass.) were 
used to establish a molecular weight calibration curve. The 
15 
hydrolysis of the polyketal copolymers was measured in buff-
ered water at pH values of 1.0 (O.lM HCL), 4.5 (100 mM 
AcOH) and 7.4 (100 mM) at 37° C. Briefly, 20 mg of the 
polymer samples were placed in a 5 ml vial, 1 mL of buffer 
s~lution was added to each vial, and mixed with a magnetic 
20 
stJr bar. At specific time points, 1 mL of CDC13 was added to 
each vial and shaken vigorously, the CDC13 phase was iso-
lated and analyzed by 1 H NMR, to determine the percent 
hydrolysis the ofketal linkages in polyketal copolymer. 
Results and Discussion 
25 
Six polyketal copolymers PK1-PK6 (Table 1, infra), based 
on PCADK, were synthesized using the acetal exchange reac-
tion. The copolymers of PCADK were synthesized by copo-
lymerizing 1,4-cyclohexanedimethanol with either butane-
diol, pentanediol, hexanediol, and octanediol. The 
30 
hydrophilicity of these dials are different from that of 1 4-
cyclohexanedimethanol (log P=l.46), as evidenced by th~ir 
respective log P values (Table 2, infra). FIG. 29 shows a 
synthetic scheme of the acetal-exchange reaction used to 
make the polyketals and the degradation products generated 
35 
from their hydrolysis. The synthesis of all the polyketal 
copolymers was accomplished in one step, on a multi-gram 
scale, and with yields of 50-60%. In general, the introduction 
of dials other than CDM did not cause any complications in 
the synthesis, and procedures developed for the synthesis of 
40 
PCADK were suitable for the synthesis of the copolymers. 
Importantly, all the copolyketals synthesized were crystal-
line, and therefore have the potential for formulation into 
microparticles. 
to the reaction, every hour for 6 hours, via a metering funnel, 45 
to compensate for 2,2-dimethoxypropane and benzene that 
had distilled off. After 24 hours, the reaction was stopped by 
adding 100 µL of triethylamine. The polymer was isolated by 
precipitation into cold hexanes and analyzed by 1 H-NMR and 
GPC, in general the resulting polymers had number average 50 
molecular weights between 2000 to 4000 Da. Table 1 lists the 
compositions and molecular weights of the polyketal copoly-
mers synthesized. 1H NMR spectra were obtained using a 
Varian Mercury VX 400 MHz 
TABLE 1 
Compositions and molecular weight of polyketal copolymers synthesized. 
n ~ 2, 3, 4, and 6 
NMR spectrometer (Palo Alto, Calif.) using CDC13 as the 55 
solvent, the H-NMR spectra of the polyketal copolymers are 
summarized below, as a representative example, the 1 H-NMR 
of P~3 is shown in FIG. 28. The molar ratio of 1,5-pen-
tanedwl to 1,4-cyclohexanedimethanol was obtained by 
obtaining the ratio of areas under the peaks a and b, respec- 60 
tively. 
PKl. 1H NMR (CDC13 ) o=3.4-3.1S (m, 4H), 1.66 (s, 1.9H), 
1.S5-0.93 (m, SH), and 1.32 (s, 6H). 
PK2. 1H NMR (CDC13 ) o=3.4-3.1S (m, 4H), 1.66 (s, 1.SH), 
1.S5-0.93 (m. SH), and 1.32 (s, 6H). 
PK3. 1H NMR (CDC13 ) o=3.4-3.1S (m, 4H), 1.64 (s, 1.7H), 










Monomer A MonomerB Mn DP! 
1,4-cyclohexanedimethanol 1,5-pentanediol 2149 1.742 
(x ~ 98.03%) (y~ 1.93%) 
1,4-cyclohexanedimethanol 1,5-pentanediol 2530 1.629 
(x ~ 92.46%) (y~ 7.56%) 
1,4-cyclohexanedimethanol 1,5-pentanediol 2596 1.432 
(x ~ 86.70%) (y ~ 13.30%) 
1,4-cyclohexanedimethanol 1,4-butanediol 2637 1.553 
(x ~ 96.75%) (y~ 3.25%) 
1,4-cyclohexanedimethanol 1,6-hexanediol 2122 1.538 
(x ~ 85.32%) (y ~ 14.68%) 
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TABLE I-continued 
Compositions and molecular weight of polyketal copolymers synthesized. 
n ~ 2, 3, 4, and 6 
Polymer Polymer composition 
ID Monomer A MonomerB DP! 
38 
To determine if this was a broader phenomenon, extending 
beyond copolymers of pentane dial, polyketal copolymers 
PK4, PK5, and PK6 were also synthesized from butanediol, 
hexanediol, and octanediol, which have differing hydropho-
5 bicity from pentanediol, and their hydrolysis kinetics were 
investigated. Table 2 demonstrates that this set of copolymers 
also has an inverse relationship between hydrophobicity and 
hydrolysis kinetics. For example, PK4, a copolymer synthe-
sized using 1,4-cyclohexanedimethanol and 1,4-butanediol, 
10 has the faster hydrolysis kinetics of all the copolyketals syn-
thesized, having a hydrolysis half-life of 1 day at pH 4.5, 
which is predicted based on the hig hydrophilicity ofbutane-
PK6 1,4-cyclohexanedimethanol 
(x ~ 87.31 %) 
1,8-octanediol 
(y ~ 12.69%) 
2181 1.786 15 
diol in comparison to the other dials. On the other hand, PK6, 
synthesized using 1,4-cyclohexanedimethanol and a more 
hydrophobic monomer, 1,8-octanediol, hada pH 4.5 hydroly-
The hydrolysis kinetics of PK! to PK6 was measured at the 
pH values of 4.5 and 7.4 to determine their behavior in the 
acidic environment of phagosomes and in the blood. FIG. 30 
demonstrates that all polyketal copolymers undergo acid-
catalyzed hydrolysis and that their hydrolysis kinetics scale 
inversely with their hydrophobicity. PK!, PK2, and PK3 were 
sis half-life of 18.6 days. In summary, these data demonstrate 
that the hydrolysis kinetics of polyketals can be tuned by 
varying their hydrophobicity and suggests that diffusion of 
20 water into the polyketals is the rate determining step govern-
ing hydrolysis. Importantly, the hydrolysis kinetics of all the 
polyketal copolymers was pH sensitive; in general they 
hydrolyzed at least one order of magnitude faster at pH 4.5 
than at pH 7.4. 
One of the polyketal copolymers synthesized (termed PK3 
in Table 1), consisting of cyclohexane-dimethanol and pen-
tane dial, had a hydrolysis half life of 2 days at pH 4.5 but 
several weeks at pH 7.4. This polyketal may be useful for 
delivering therapeutic drugs to a subject because it should 
copolymers synthesized from 1,4-cyclohexanedimethanol 25 
and 1,5-pentanediol. Their hydrophilicity scales with their 
1,5-pentanediol content, due to the large difference in hydro-
phobicity between 1,5-pentanediol and 1,4-cyclohex-
anedimethanol, their respective Log P values are 0.27 and 
1.46. FIG. 30A demonstrates that 1,5-pentanediol dramati-
cally accelerates the pH 4.5 hydrolysis kinetics of 1,4-cyclo-
hexanedimethanol based polyketals. For example, only 30% 
30 hydrolyze rapidly after phagocytosis; however it is relatively 
stable at physiological pH. Additionally, PK3 may be suitable 
for microparticle drug delivery because ofits rapid hydrolysis 
kinetics and biocompatible degradation products, which are of PK!, a copolymer containing 2% pentanediol, was hydro-
lyzed after 10 days at pH 4.5. On the other hand, at the same 
pH condition PK2, which contains 7 .5% pentanediol, was 
75% hydrolyzed after 7 days, and PK3, containing 13% pen-
tanediol, was 50% hydrolyzed after 2 days and completely 
hydrolyzed after 5 days. For all three polyketals, less than 
15% of the polymers were hydrolyzed in pH 7.4 within the 
duration of the experiments (FIG. 30B). 
35 
1,5-pentanediol, 1,4-cyclohexanedimethanol, and acetone. 
To further the study of using PK3 for delivery of drug 
therapies, microparticles were formulated from PK3 using a 
solvent evaporation procedure. FIG. 31 demonstrates that 
microparticles can be formed with PK3, and that the particles 
40 
have a size between 1-5 microns, which suitable for phago-
cytosis by macrophages. Thus, therapeutic drugs may be 
encapsulated into PK3 microparticles (for example by using 
TABLE2 
Hydrolysis half-lives of polyketal copolymers at pH 4.5 and pH 7.4. at 37° C. 
Pol mer com osition Estimated Log P 
Percent Percent Half life half life at ofdiol 
PKID DiolA diolA DiolB diolB at pH 4.5 pH 7.4 B 
PK4 96.75% HO~ 3.25% 1.0 day 54 days -0.83 
OH 
1,4-butanediol 
PK3 86.70 HO~OH 13.30% 1.8 days 39 days 0.27 OH~ 
OH 
1,4-cyclohexane dimethanol 1,5-pentanediol 
PK5 85.32% HO~ 14.68% 4.4 days 53 days 0.76 
OH 
1,6-hexanediol 
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a water/oil/water double emulsion procedure or other 
method) for administration into a subject. 
Microparticles loaded with active agents will be formu-
lated from the polyketal copolymers using a modified water/ 
oil/water emulsion method (Ando et al., Journal of Pharma- 5 
ceutical Sciences 1999, 88, 126-130). For example, PK3 (100 
mg) will be dissolved in 1 mL of dichloromethane, in a 
separate vial, 40 mg of the active agent will be dissolved in 
400 µL ofD.I. water. The aqueous solution of the active agent 
will be mixed with the PK3 solution, and sonicated for 60 10 
seconds (Misonix Incorporated, Farmigdale, N.Y.). The soni-
cated mixture will then immersed in liquid nitrogen for 15 
sec, and 12 mL ofa 5% w/w PVA solution (pH 7.45) will be 
added to it. This mixture will be homogenized for 120 sec-
onds with a Powergen 500 homogenizer (Fisher Scientific, 15 
Waltham, Mass.), and then transferred to a beaker containing 
40 mL of 1% w/w PVA (pH 7.45). This solution will then be 
stirred for 3 hours with a magnetic stir bar to evaporate the 
organic solvent. The particles will be isolated by centrifuging 
at 10,000 rmp for 15 min, washed twice with 15 mL of PBS 20 
buffer and freeze dried. 
REFERENCES FOR EXAMPLE 7 
40 
(Avanti Polar Lipids) in dichloromethane (final concentration 
of 10% DOGS-NTA). To ensure solubility, the mixture was 
sonicated for several seconds/minutes in a water bath sonica-
tor. The polymer solution was then poured into a vial contain-
ing 5 mL of PVA (2%) andhomogenizedfor60 seconds. The 
resulting solution was stirred over 40 mL of 0.5% PVA for 4-6 
hours. The particles were then spun down and washed several 
times in deionized water and frozen in liquid nitrogen for 
lyophilization. The resulting freeze-dried particles were 
imaged using SEM and shown in FIG. 34. 
Nickel loading of PCADK-NTA 
In order to get particles capable of binding to His-tagged 
proteins, particles needed to be loaded with nickel. Thus, 
particles were incubated with 50 mM NiC12 at 10 mg/mL and 
agitated for 2 hours at room temperature. To determine nickel 
uptake, we incubated the particles overnight with NiC12 , spun 
down the particles, and measured the unbound nickel in the 
supernatant spectrophotometrically. As the data in FIG. 35 
demonstrate, at varying NTA loading there was a decrease in 
free nickel in the solution, indicating the particles had been 
loaded with nickel. 
Binding of His-Tagged Proteins to PCADK-NiNTA 
To determine ifNiNTA on particles was capable of binding 
Cordes, E. H.; Bull, H. Chemical Reviews 1974, 74, 581. 
Gopferich, A. Bio materials 1996, 17, 103. 
Gopferich, A.; Tessmar, J. Advanced Drug Delivery Reviews 
2002,54,911. 
Kumar, N.; Langer, R. S.; Domb, A. J. Advanced Drug Deliv-
ery Reviews 2002, 54, 889. 
25 His-tagged proteins, varying concentrations ofHis-GFP were 
incubated with PCADK-NiNTA (1 % solution w/v) overnight 
at 4 degrees Celsius. Particles were centrifuged out and 
washed several times in PBS before resuspension for analy-
sis. FIG. 36 is a representative fluorescent stain for GFP that 
Example 8 
Formation of Particles with Linkers 
In this example, a polyketal molecule of the invention was 
modified with a linker that can bind an active agent. Specifi-
cally, a nitrilotriacetic acid (NTA) linker was added to 
PCADK. The NTA linker, when loaded with nickel (Ni) 
allowed the binding of histidine-tagged proteins (FIG. 32). 
The modified PCADK then formed microspheres ideal for 
rapid delivery ofactive agents (e.g. growth factors) (FIG. 33). 
Materials and Methods 
Synthesis of PCADK Particles with NTA Linker 
30 was converted to grayscale for presentation. As the image 
shows, the particles retained GFP on their surface. To further 
quantify the amount ofHis-GFP bound, particles were loaded 
with increasing amounts of His-GFP, washed several times, 
35 
and ELISA was run on the particles to determine levels of 
binding. As the data in FIGS. 37 (1% NTA) and 38 (10% 
NTA) show, PCADK-NiNTA dose-dependently bound the 
His-tagged protein. At 1 % NTA, the particles saturated bind-
ing at a loading of 60 ng His-GFP, while at 10% NTA, satu-
40 ration was reached at 120 ng His-GFP loading. At most points 
in the linear range, binding was roughly 50% efficient. The 
data in FIG. 40 shows that the percent binding of His-GFP 
increases with the amount ofNTA. FIG. 41 shows that His-
GFP binding to NTA is stable for at least 15 hours. 
PCADK was synthesized as previously described above 45 
(see also Lee Set al. Polyketal microparticles: a new delivery 
vehicle for superoxide dismutase. Bioconjug Chem. 2007 
January-February; 18(1):4-7 and Heffernan M J and Murthy 
To determine if the binding was reversible, various NTA 
concentration His-GFP-loaded particles were incubated with 
imidazole (200 mM), a competitive agent for the Ni-NTA 
complex. Supernatants were collected at various time points 
and assayed for GFP fluorescence. As the data in FIG. 39 
demonstrate, the His-GFP was released from the particles 
rather rapidly, with most of the protein released at 30 minutes. 
N. Polyketal nanoparticles: a new pH-sensitive biodegradable 
drug delivery vehicle. Bioconjug Chem. 2005 November- 50 
December; 16(6):1340-2, herein incorporated by reference). 
After synthesis of the polyketal, 90 mg of PCADK was 
dissolved in 1 mL of a 10 mg/mL solution of DOGS-NTA 
<160> NUMBER OF SEQ ID NOS, 
<210> SEQ ID NO 1 
<211> LENGTH, 8 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Micelle Encapsulated Peptide 
This suggests that the protein is not irreversibly bound to the 
particle and should have good bioavailability. 
41 
<400> SEQUENCE, 1 
Ser Ile Ile Asn Phe Glu Lys Leu 
1 5 
<210> SEQ ID NO 2 
<211> LENGTH, 14 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 8,252,846 B2 
-continued 
<223> OTHER INFORMATION, Diacylated Lipopetide 
<400> SEQUENCE, 2 
Cys Gly Asn Asn Asp Glu Ser Asn Ile Ser Phe Lys Glu Lys 
1 5 10 
<210> SEQ ID NO 3 
<211> LENGTH, 16 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Diacylated Lipopeptide 
<400> SEQUENCE, 3 
Cys Gly Asn Asn Asp Glu Ser Asn Ile Ser Phe Lys Glu Lys Ser Lys 
1 5 10 15 
<210> SEQ ID NO 4 
<211> LENGTH, 22 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, HIV peptide 
<400> SEQUENCE, 4 
Cys Gly Cys Arg Ile Gln Arg Gly Pro Gly Arg Ala Phe Val Thr Ile 
1 5 10 15 
Gly Lys Cys Gly Cys Gly 
20 
<210> SEQ ID NO 5 
<211> LENGTH, 15 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, GP-120 protein 
<400> SEQUENCE, 5 
Arg Ile Gln Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Gly Lys 
1 5 10 15 
<210> SEQ ID NO 6 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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What is claimed is: 
1. A biodegradable hydrophobic polyketal polymer com-
prising ketal groups, wherein each ketal group of the polymer 
has two oxygen atoms within the polymer backbone, wherein 
the polyketal polymer is selected from a group consisting of: 5 
a. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,5-pentanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,5-pentanedioxy is a poly( cyclohex-
ane-1,4-diyl acetone dimethylene ketal-co-1,5-pentane- 10 
acetone dimethylene ketal); 
b. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,4-butanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,4-butanedioxy is a poly(cyclohex- 15 
ane-1,4-diyl acetone dimethylene ketal-co-1,4-butane-
acetone dimethylene ketal); 
c. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,6-hexanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex- 20 
anedimethoxy and 1,6-hexanedioxy is a poly( cyclohex-
ane-1,4-diyl acetone dimethylene ketal-co-1,6-hexane-
acetone dimethylene ketal; and 
d. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,8-octanedioxy, wherein the 25 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,8-octanedioxy is a poly(cyclohex-
ane-1,4-diyl acetone dimethylene ketal-co-1,8-octane-
acetone dimethylene ketal). 
2. The polymer of claim 1, further comprising a linker. 30 
3. The polymer of claim 2, wherein the linker is streptavi-
din, RDG, GST, ssDNA, hemoglobin, an amino acid 
sequence, an antibody, a polycarboxylic acid and/or a chelat-
ing agent. 
4. The polymer of claim 2, wherein the linker binds a 35 
protein, peptide and/or carbohydrate. 
5. The polymer of claim 4, wherein the protein, peptide 
and/or carbohydrate comprises a histidine tag. 
6. The polymer of claim 4, wherein said protein is a thera-
peutic, prophylactic or diagnostic protein. 40 
7. The polymer of claim 4, wherein said protein, peptide, 
and/or carbohydrate is a growth factor, cytokine, antioxidant 
enzyme, or antibody. 
8. A biodegradable particle comprising 
(a) a biodegradable hydrophobic polyketal polymer com- 45 
prising ketal groups, wherein each ketal group of the 
polymer has two oxygen atoms within the polymer 
backbone, wherein the polyketal polymer is selected 
from a group consisting of: 
1. a polyketal polymer comprising 1,4,-cyclohex- 50 
anedimethoxy and 1,5-pentanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,5-pentanedioxy is a poly(cyclo-
hexane-1,4-diyl acetone dimethylene ketal-co-1,5-
pentane-acetone dimethylene ketal); 55 
ii. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,4-butanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,4-butanedioxy is a poly(cyclo-
hexane-1,4-diyl acetone dimethylene ketal-co-1,4- 60 
butane-acetone dimethylene ketal); 
iii a polyketal polymer comprising 1,4,-cyclohex-
anedirnethoxy and 1,6-hexanedioxy, wherein the 
polyketal polymer compnsmg 1,4-cyclohex-
anedimethoxy and 1,6-hexanedioxy is a poly( cyclo- 65 
hexane-1,4-diyl acetone dimethylene ketal-co-1,6-
hexane-acetone dimethylene ketal); and 
44 
iv. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,8-octanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,8-octanedioxy is a poly( cyclo-
hexane-1,4-diyl acetone dimethylene ketal-co-1,8-
octane-acetone dimethylene ketal), and 
(b) a linker. 
9. The particle of claim 8, wherein the linker binds a pro-
tein, peptide and/or carbohydrate. 
10. A composition comprising 
a. a biodegradable hydrophobic polyketal polymer com-
prising ketal groups, wherein each ketal group of the 
polymer has two oxygen atoms within the polymer 
backbone, wherein the polyketal polymer is selected 
from a group consisting of: 
1. a polyketal polymer comprising 1,4 ,-cyclohex-
anedimethoxy and 1,5-pentanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,5-pentanedioxy is a poly(cyclo-
hexane-1,4-diyl acetone dimethylene ketal-co-1,5-
pentane-acetone dimethylene ketal); 
ii. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,4-butanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,4-butanedioxy is a poly(cyclo-
hexane-1,4-diyl acetone dimethylene ketal-co-1,4-
butane-acetone dimethylene ketal); 
iii. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,6-hexanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,6-hexanedioxy is a poly( cyclo-
hexane-1,4-diyl acetone dimethylene ketal-co-1,6-
hexane-acetone dimetylene ketal); and 
iv. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,8-octanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,8-octanedioxy is a poly( cyclo-
hexane-1,4-diyl acetone dimethylene ketal-co-1,8-
octane-acetone dimethylene ketal), 
b. a linker, and 
c. a protein, peptide and/or carbohydrate attached to the 
linker. 
11. The composition of claim 10, wherein the linker is 
streptavidin, RDG, GST, ssDNA, hemoglobin, an amino acid 
sequence, an antibody, a polycarboxylic acid and/or a chelat-
ing agent. 
12. A biodegradable particle comprising 
(a) a biodegradable hydrophobic polyketal polymer com-
prising ketal groups, wherein each ketal group of the 
polymer has two oxygen atoms within the polymer 
backbone, wherein the polyketal polymer is selected 
from a group consisting of: 
1. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,5-pentanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,5-pentanedioxy is a poly(cyclo-
hexane-1,4-diyl acetone dimethylene ketal-co-1,5-
pentane-acetone dimethylene ketal); 
ii a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,4-butanedioxy, wherein the 
polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,4-butanedioxy is a poly(cyclo-
hexane-1,4-diyl acetone dimethylene ketal-co-1,4-
butane-acetone dimethylene ketal); 
iii. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,6-hexanedioxy, wherein the 
US 8,252,846 B2 
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polyketal polymer compnsmg 1,4,-cyclohex-
anedimethoxy and 1,6-hexanedioxy is a poly( cyclo-
hexane-1,4-diyl acetone dimethylene ketal-co-1,6-
hexane-acetone dimethylene ketal); and 
iv. a polyketal polymer comprising 1,4,-cyclohex-
anedimethoxy and 1,8-octanedioxy, wherein the 
polyketal polymer comprising 1,4,-cyclohex-
46 
anedimethoxy and 1,8-octanedioxy is a poly( cyclo-
hexane-1,4-diyl acetone dimethylene ketal-co-1,8-
octane-acetone dimethylene ketal); and 
(b) an active agent selected from a group consisting of a 
protein, peptide, carbohydrate, nucleic acids, or small 
molecules. 
* * * * * 
